aid,aidtype,aidname,aiddesc,aidsrcid,aidsrcname,aidextid,aidmdate,cids,sids,geneids,aidcategories,protacxns,depcatg,pmids,rnai,ecs,repacxns,taxids,cellids,targettaxid,annotation,partial_agonist_desc,partial_agonist_aidname,agonist_desc,agonist_aidname,antagonist_desc,antagonist_aidname
61173,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL671178,20180930,10247719|44319102|44319361|44319368|44319369|44319370,103290121|103290648|103290659|103290661|103290663|103677635,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
61302,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells; Low binding affinity,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL671646,20180930,54562,103543557,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
61303,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells; high binding affinity,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL671647,20180930,54562,103543557,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
61311,Confirmatory,Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone,Title: New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates._||_Abstract: Described in this report is a systematic study which led to the identification of two new dopamine D2 partial agonists (5 and 17). Phenols 5 and 17 represent prototypes of two new classes of D2 partial agonists as well as templates for the future design of novel dopaminergic agents.,43,ChEMBL,CHEMBL671654,20180909,511484|8529065|8690650|10015867|10378389|10612157|11776546|15034333|20256387|44332565|44332566|44332581|44332613|44332646|44332686|44332701,103251600|103251646|103252486|103300035|103318633|103318634|103318671|103318672|103318777|103318778|103318842|103318843|103318880|103318995|103318996|103319034,1813,,P14416,Curation Efforts|Research and Development,9871673,0,,P14416,,197.0,,,1,0,1,0,0,0
61488,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL665385,20180930,10247719|44319102|44319361|44319368|44319369|44319370,103290121|103290648|103290659|103290661|103290663|103677635,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
61489,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells; Low binding affinity,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL875028,20180930,54562,103543557,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
61490,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells; high binding affinity,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL665386,20180930,54562,103543557,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
61621,Confirmatory,The compound was tested for binding affinity against human Dopamine receptor D2L,"Title: N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents._||_Abstract: A series of N-substituted 1-(2,3-dihydro-1, 4-benzodioxin-2-yl)methylamine derivatives with D(2) antagonist/5-HT(1A) partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D(2), D(3), and 5-HT(1A) receptors but significantly less affinity for human alpha(1) adrenoceptors and rat H(1) and muscarinic receptors. In rodents, 24 showed functional D(2)-like antagonism and 5-HT(1A) partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.",43,ChEMBL,CHEMBL669156,20181016,9865858,103337393,1813,,P14416,Curation Efforts|Research and Development,10464021,0,,P14416,,,,,1,0,1,0,1,0
62758,Confirmatory,Inhibition of [3H]thymidine uptake by Dopamine receptor D2,"Title: 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists._||_Abstract: A series of arylpiperazines and tetrahydropyridines joined to indoles by semirigid cycloalkyl spacers were prepared. Target compounds were studied for their ability to bind to the DA D2 receptor in vitro and to inhibit dopamine synthesis and spontaneous locomotor activity in rats. Effects of tether length and relative stereochemistry were assessed for a series of 2-pyridylpiperazines. The cyclohexylethyl spacer was found to be the most active in the series. Further studies explored effects of changes in the arylpiperazine and indole portions of the molecule. From these studies trans-2-[[4-(1H-3-indolyl)cyclohexyl]ethyl]-4- (2-pyridinyl)piperazine (30a) was selected for further evaluation. It was characterized as a partial agonist of DA D2 receptors in vitro and caused decreases in dopamine synthesis and release as well as dopamine neuronal firing. Compound 30a was shown to be devoid of behavioral effects associated with postsynaptic DA D2 receptor activation. Furthermore, compound 30a was shown both to decrease DA synthesis and to inhibit Sidman avoidance responding in squirrel monkeys. These findings suggest that DA D2 partial agonists with the appropriate level of intrinsic activity can act to decrease dopamine synthesis and release and may have potential utility as antipsychotic agents.",43,ChEMBL,CHEMBL671064,20181015,9886609,103293659,1813,,P14416,Curation Efforts|Research and Development,9003524,0,,P14416,,,,,1,0,1,0,0,0
62761,Confirmatory,The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2,"Title: Aminopyrimidines with high affinity for both serotonin and dopamine receptors._||_Abstract: A series of [4-[2(4-arylpiperazin-1-yl)alkyl]cyclohexyl]pyrimidin-2-ylamine s was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.",43,ChEMBL,CHEMBL671067,20181016,3075615|10522950,103418630|103419084,1813,In vitro,P14416,Curation Efforts|Research and Development,9513604,0,,P14416,,198.0,,,1,0,1,0,0,0
62772,Confirmatory,The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2,"Title: Aminopyrimidines with high affinity for both serotonin and dopamine receptors._||_Abstract: A series of [4-[2(4-arylpiperazin-1-yl)alkyl]cyclohexyl]pyrimidin-2-ylamine s was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.",43,ChEMBL,CHEMBL670114,20181016,10738750|11795011,103418736|103419722,1813,In vitro,P14416,Curation Efforts|Research and Development,9513604,0,,P14416,,198.0,,,1,0,1,0,0,0
62896,Literature-derived,Percentage intrinsic activity measured at DA D2 receptor by measuring its ability to inhibit [3H]-thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2,"Title: Aminopyrimidines with high affinity for both serotonin and dopamine receptors._||_Abstract: A series of [4-[2(4-arylpiperazin-1-yl)alkyl]cyclohexyl]pyrimidin-2-ylamine s was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.",43,ChEMBL,CHEMBL672747,20181016,3075615|10522950|10738750|11795011,103418630|103418736|103419084|103419722,1813,,P14416,Curation Efforts|Research and Development,9513604,0,,P14416,,198.0,,,1,0,1,0,0,0
62901,Confirmatory,Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells,"Title: 2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356._||_Abstract: Solution-phase synthesis and a solid-phase supported approach to piperazinylmethyl substituted pyrroles are described. Receptor binding studies and the measurement of D4 ligand efficacy led to the ethynylpyrrole 1d (FAUC 356) exerting selective D4 binding and substantial ligand efficacy (66%, EC(50)=1.9nM). This activity profile might be of interest for the treatment of ADHD.",43,ChEMBL,CHEMBL671363,20180930,10378194|10404144|11405107|12997400|44300865|44301054|71458071|135398737,103165765|103165864|103246744|103246789|103247241|103247257|103247486|163329796,1813,,P14416,Curation Efforts|Research and Development,12113813,0,,P14416,,197.0,,,1,0,1,0,0,0
62902,Literature-derived,Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells; 64/3100,"Title: 2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356._||_Abstract: Solution-phase synthesis and a solid-phase supported approach to piperazinylmethyl substituted pyrroles are described. Receptor binding studies and the measurement of D4 ligand efficacy led to the ethynylpyrrole 1d (FAUC 356) exerting selective D4 binding and substantial ligand efficacy (66%, EC(50)=1.9nM). This activity profile might be of interest for the treatment of ADHD.",43,ChEMBL,CHEMBL671364,20180930,54562,103543557,1813,,P14416,Curation Efforts|Research and Development,12113813,0,,P14416,,197.0,,,1,0,1,0,0,0
62903,Confirmatory,Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells,"Title: 2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356._||_Abstract: Solution-phase synthesis and a solid-phase supported approach to piperazinylmethyl substituted pyrroles are described. Receptor binding studies and the measurement of D4 ligand efficacy led to the ethynylpyrrole 1d (FAUC 356) exerting selective D4 binding and substantial ligand efficacy (66%, EC(50)=1.9nM). This activity profile might be of interest for the treatment of ADHD.",43,ChEMBL,CHEMBL671365,20180930,10378194|10404144|11405107|12997400|44300865|44301054|71458071|135398737,103165765|103165864|103246744|103246789|103247241|103247257|103247486|163329796,1813,,P14416,Curation Efforts|Research and Development,12113813,0,,P14416,,197.0,,,1,0,1,0,0,0
62904,Literature-derived,Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells; 52/4000,"Title: 2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356._||_Abstract: Solution-phase synthesis and a solid-phase supported approach to piperazinylmethyl substituted pyrroles are described. Receptor binding studies and the measurement of D4 ligand efficacy led to the ethynylpyrrole 1d (FAUC 356) exerting selective D4 binding and substantial ligand efficacy (66%, EC(50)=1.9nM). This activity profile might be of interest for the treatment of ADHD.",43,ChEMBL,CHEMBL671366,20180930,54562,103543557,1813,,P14416,Curation Efforts|Research and Development,12113813,0,,P14416,,197.0,,,1,0,1,0,0,0
62908,Confirmatory,Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.,"Title: Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents._||_Abstract: The discovery of a series of chromeno[3,4-c]pyridin-5-ones with selective affinity for the dopamine D4 receptor is described. Target compounds were tested for binding to cloned human dopamine D2, D3, and D4 receptor subtypes expressed in Chinese hamster ovary (CHO) K-1 cells. Several compounds demonstrated single digit nanomolar Ki values for binding to the D4 receptor with several hundred-fold selectivities toward the D2 and D3 receptors. A limited SAR study of this series is discussed. In a mitogenesis assay measuring [3H]thymidine uptake, the target compounds showed antagonist to weak partial agonist activity at the D4 receptor, with intrinsic activities ranging from 0 to 35%. Compound 6, 3-benzyl-8-methyl-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippocampus and 10% in the striatum of rat brain when dosed orally at 10 mg/kg.",43,ChEMBL,CHEMBL671369,20181015,3559|9883587|9995264|10042972|10318141|10450880|10567839|10568805|10570898|10620139|10640530|10641954|10641955|10665626|10687362|10689266|10759511|10786591|10807035|135398737,103165765|103167216|103299733|103299760|103299908|103300250|103300277|103300279|103300334|103300347|103300348|103300385|103300386|103300398|103300416|103300419|103300452|103300480|103300685|103300708,1813,In vitro,P14416,Curation Efforts|Research and Development,9276014,0,,P14416,,197.0,,,1,0,1,0,1,0
62917,Confirmatory,Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.,"Title: (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents._||_Abstract: The discovery of a series of novel (aryloxy)alkylamines with selective affinity for the dopamine D4 receptor is described. Target compounds were tested for binding to cloned human dopamine D2, D3, and D4 receptor subtypes expressed in Chinese hamster ovary (CHO) K-1 cells. A number of compounds demonstrated subnanomolar Ki values for binding to the D4 receptor, with several 100-fold selectivities toward the D2 and D3 receptors. Several compounds with combined D3/D4 receptor binding selectivity were also identified. A limited structure-activity relationship study of this chemical series is discussed. In a mitogenesis functional assay, the effect of the test compounds on cellular uptake of [3H]thymidine in D4-transfected CHO 10,001 cells was measured and compared to the response of the full dopamine agonist quinpirole. The activity of the compounds varied from full antagonist to weak partial agonist activity (intrinsic activity of 0-19% in comparison to quinpirole).",43,ChEMBL,CHEMBL671378,20181015,3559|9948461|9948965|10315310|10447709|10450892|10494394|10498972|10518406|10542345|10548105|10588194|10589218|10590285|10615787|10636896|10638052|10660814|10684706|10708280|10732925|10733406|10734727|10758004|10780510|10780942|10782049|10805355|135398737,103165765|103167216|103189602|103363609|103363611|103363638|103363808|103363828|103363829|103363830|103363891|103363893|103363899|103363918|103363921|103363922|103363949|103364010|103364038|103364039|103364100|103364101|103364142|103364237|103364476|103364506|103364507|103364550|103364591,1813,,P14416,Curation Efforts|Research and Development,9406594,0,,P14416,,198.0,,,1,0,1,0,1,0
62919,Confirmatory,Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells,"Title: N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands._||_Abstract: A series of N(1)-arylsulfonyltryptamines were found to be potent ligands of the human serotonin 5-HT(6) receptor with the 5-methoxy-1-benzenesulfonyl analogue (19) having the highest affinity. Additionally, it was discovered that a group such as 3-(3-methoxybenzyl)-1,2,4-oxadiazol-5-yl in the 2-position of the indole ring (43) can replace the arylsulfonyl substituent in the 1-position with no loss of affinity. This suggested that the binding conformation of the aminoethyl side chain at this receptor was toward the 4-position of the indole ring and was supported by the fact that the 4-(aminoethyl)indoles (45) also displayed high affinity, as did the conformationally rigid 1,3,4,5-tetrahydrobenz[c,d]indole (49). Molecular modeling showed that 19, 43, and 45 all had low-energy conformers that overlaid well onto 49. Both 19 and 49 had good selectivity over other serotonin receptors tested, with 49 also showing excellent selectivity over all dopamine receptors. In a functional adenylate cyclase stimulation assay, 19 and 49 had no agonist activity, whereas 45 behaved as a partial agonist. Finally, it was shown that 19 had good activity in the 5-HT(2A) centrally mediated mescaline-induced head twitch assay, which implies that it is brain-penetrant.",43,ChEMBL,CHEMBL671380,20181017,6918542|6918601|9796627|9817810|9862256|9867475|9927441|11747350,103272941|103307795|103307845|103308762|103359034|103359133|103359157|103359196,1813,,P14416,Curation Efforts|Research and Development,11689074,0,,P14416,,197.0,,,1,0,1,0,0,0
62923,Confirmatory,Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.,"Title: New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans._||_Abstract: A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high- and low-affinity agonist states (D2High and D2Low, respectively) of the dopamine (DA) D2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D2High receptor vs the 5HT1A and alpha 1 receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D2High receptor vs the alpha 1 and 5HT1A receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D2 agonist pharmacophoric criteria and was proposed as the D2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo- and hyperdopaminergic activity, without the side effects associated with complete D2 agonism or antagonism.",43,ChEMBL,CHEMBL671384,20181015,44356070|44356132|44356133|44356141|44356251|44356265|44356285|44356290,103371281|103371405|103371406|103371430|103371644|103371668|103371710|103371720,1813,,P14416,Curation Efforts|Research and Development,9435894,0,,P14416,,,,,1,0,1,0,1,0
62927,Confirmatory,Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells,"Title: N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands._||_Abstract: The dopamine D(3) receptor is recognized as a potential therapeutic target for the treatment of various neurological and psychiatric disorders. Targetting high affinity and D(3) versus D(2) receptor-preferring ligands, the partial agonist BP 897 was taken as a lead structure. Variations in the spacer and the aryl moiety led to N-alkylated 1-(2-methyoxyphenyl)piperazines with markedly improved affinity and selectivity. Molecular modeling studies supported the structural development. Pharmacophore models for dopamine D(2) and D(3) receptor ligands were developed from their potentially bioactive conformation and were compared in order to get insight into molecular properties of importance for D(2)/D(3) receptor selectivity. For the 72 compounds presented here, an extended and more linear conformation in the aliphatic or aryl spacers turned out to be crucial for dopamine D(3) receptor selectivity. Structural diversity in the aryl moiety (benzamides, heteroarylamides, arylimides) had a major influence on (sub)nanomolar D(3) receptor affinity, which was optimized with more rigid aryl acrylamide derivatives. Compound 38 (ST 280, (E)-4-iodo-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)cinnamoylamide) displayed a most promising pharmacological profile (K(i) (hD(3)) = 0.5 nM; K(i) (hD(2L)) = 76.4 nM; selectivity ratio of 153), and above that, compound 38 offered the prospect of a novel radioligand as a pharmacological tool for various D(3) receptor-related in vitro and in vivo investigation.",43,ChEMBL,CHEMBL671730,20181017,3038495|9827991|10368423|10874342|10905430|10919602|10939008|10940279|10949917|10951185|10960767|10961112|10971923|10983103|10994916|11027407|11091160|11102188|11102301|11113582|11730189|11733372|11761374|11761412|11812299|11812905|11826347|11826673|21219157|44329321|44350586|44350625|44350653|44350660|44350674|44350675|44350679|44350685|44350714|44350728|44350752|44350754|44350759|44350773|44350774|44350782|44350788|44350795|44350796|44350798|44350799|44350806|44350824|44350826|44350835|44350839|44350841|44350842|44350843|44350845|44350849|44350852|44350861|44350867|44350871|44350874|44350875|44350888|44350889|44350908|44350909|44350919|44350920|44351005,103192597|103194907|103197235|103311769|103358646|103358762|103358789|103358854|103358867|103358870|103358895|103358896|103358898|103358944|103358948|103358949|103358956|103358966|103358967|103358971|103358988|103359060|103359061|103359092|103359193|103359199|103359208|103359239|103359240|103359265|103359266|103359272|103359281|103359298|103359310|103359311|103359313|103359314|103359332|103359336|103359337|103359338|103359342|103359345|103359378|103359402|103359405|103359420|103359431|103359434|103359435|103359437|103359440|103359452|103359465|103359467|103359487|103359489|103359497|103359505|103359507|103359516|103359527|103359530|103359567|103359568|103359569|103359570|103359571|103359614|103359615|103359649|103359650|103359793|103359830,1813,,P14416,Curation Efforts|Research and Development,12930150,0,,P14416,,197.0,,,1,0,1,0,0,0
62931,Confirmatory,Binding affinity against human Dopamine receptor D2 using [3H]spiperone as radioligand,"Title: Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning._||_Abstract: A series of subtype selective dopamine D(4) receptor ligands from the hetroarylmethylphenylpiperazine class have been discovered that exhibit a remarkable structure-activity relationship (SAR), revealing a substituent effect in which regiosubstitution on the terminal arylpiperazine ring can modulate functional or intrinsic activity. Other structure-dependent efficacy studies in the dopamine D(4) field have suggested a critical interaction of the heteroarylmethyl moiety with specific protein microdomains in controlling intrinsic activity. Our studies indicate that for some binding orientations, the phenylpiperazine moiety also plays a key role in determining efficacy. These data also implicate a kinetic or efficiency term, contained within measured functional affinities for agonists, which support a sequential binding and conformational stabilization model for receptor activation. The structural similarity between partial agonist and antagonist, within this subset of ligands, and lack of bioisosterism for this substituent effect are key phenomena for these hypotheses.",43,ChEMBL,CHEMBL672347,20181018,2099556|5311200|9945233|10064981|10336538|44315403,103165750|103276945|103277054|103277104|103277219|103277288,1813,,P14416,Curation Efforts|Research and Development,15084133,0,,P14416,,,,,1,0,1,0,1,0
63062,Confirmatory,Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells,"Title: Thiazoles and thiopyridines: novel series of high affinity h5HT(7) ligands._||_Abstract: A series of thiazole based 5HT(7) ligands has been identified from screening. Optimisation of the pendent aryl group and modification of the core gave a related series of high affinity, selective thiopyridine based 5HT(7) ligands, the most active of which behaves as a partial agonist.",43,ChEMBL,CHEMBL672171,20181001,435595|452533|9881600|10015688|15803947|44374207|44374225|44374233|44374299,103411603|103411615|103411642|103411670|103411706|103411718|103411720|103411825|103411843,1813,,P14416,Curation Efforts|Research and Development,14741267,0,,P14416,,197.0,,,1,0,1,0,0,0
63083,Confirmatory,"Compound was tested to inhibit Dopa accumulation in to Dopamine receptor D2 at 10 mg/kg, sc","Title: New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans._||_Abstract: A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high- and low-affinity agonist states (D2High and D2Low, respectively) of the dopamine (DA) D2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D2High receptor vs the 5HT1A and alpha 1 receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D2High receptor vs the alpha 1 and 5HT1A receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D2 agonist pharmacophoric criteria and was proposed as the D2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo- and hyperdopaminergic activity, without the side effects associated with complete D2 agonism or antagonism.",43,ChEMBL,CHEMBL672799,20181015,44356252,103371645,1813,,P14416,Curation Efforts|Research and Development,9435894,0,,P14416,,,,,1,0,1,0,1,0
63223,Confirmatory,Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2,"Title: Aminopyrimidines with high affinity for both serotonin and dopamine receptors._||_Abstract: A series of [4-[2(4-arylpiperazin-1-yl)alkyl]cyclohexyl]pyrimidin-2-ylamine s was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.",43,ChEMBL,CHEMBL672206,20181016,3075615|9865584|10497177|10499950|10522950|10570997|10596978|10598935|10618928|10642428|10643047|10712078|10713960|10736673|10738750|10740593|10756932|10765237|10785202|10786891|10854386|11794122|11795011,103281378|103281824|103418630|103418736|103418761|103418762|103418770|103418771|103418775|103418828|103418957|103418962|103418989|103418990|103419083|103419084|103419165|103419166|103419287|103419320|103419721|103419722|160698584|194165546,1813,,P14416,Curation Efforts|Research and Development,9513604,0,,P14416,,198.0,,,1,0,1,0,0,0
63854,Confirmatory,Effective dose was measured by the stimulation of mitogenesis at Dopamine receptor D4.2,"Title: Cyanoindole derivatives as highly selective dopamine D(4) receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments._||_Abstract: Traceless linking of diethoxymethyl (DEM)-protected 5- and 6-cyanoindoles and subsequent incorporation of phenylpiperazine derivatives led to the 2- and 3-piperazinylmethyl-substituted cyanoindoles 3a-m. Dopamine receptor binding studies on the final products 3a-m clearly indicated strong and selective recognition of the D(4) subtype which is known as a promising target for the treatment of neuropsychiatric disorders. The most interesting binding properties were observed for the 2-aminomethyl-5-cyanoindoles FAUC 299 (3f) and FAUC 316 (3j) (K(i) = 0.52 and 1.0 nM, respectively) when the fluoro derivative 3j proved extraordinary selectivity over D(1), D(2long), D(2short), and D(3) (>8600). To determine ligand efficacy, mitogenesis experiments were performed indicating partial agonist effects for the test compounds 3f,j (35% and 30%, when compared to the full agonist quinpirole).",43,ChEMBL,CHEMBL675193,20181016,54562,103543557,1813,,P14416,Curation Efforts|Research and Development,11087581,0,,P14416,,,,,1,0,1,0,0,0
64001,Confirmatory,Ability to displace [3H]YM-0915 from Dopamine receptor D2,"Title: New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization._||_Abstract: A series of benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives were prepared and evaluated to determine the necessary requirements for high affinity on the 5-HT(4) receptors and high selectivity versus other receptors. The compounds were synthesized by substituting the chlorine atom of benzonaphthyridines and azepinoquinolines with various N-alkyl-4-piperidinylmethanolates. They were evaluated in binding assays with [(3)H]GR 113808 as the 5-HT(4) receptor radioligand. The affinity values (K(i) or inhibition percentages) depended upon the substituent on the aromatic ring on one hand and the substituent on the lateral piperidine chain on the other hand. A chlorine atom produced a marked drop in activity while a N-propyl or N-butyl group gave compounds with nanomolar affinities (1 < K(i) < 10 nM). Among the most potent ligands (3a, 4a, 5a), 4a was selected on the basis of its high affinity and selectivity for pharmacological screening and was evaluated in vivo in specific tests. This compound reveals itself as an antagonist/low partial agonist in the COS-7 cells stably expressing the 5-HT(4(a)) receptor. Derivative 4a also showed in vivo potent analgesic activity in the writhing test at very low doses.",43,ChEMBL,CHEMBL670685,20181017,9881053,103208887,1813,,P14416,Curation Efforts|Research and Development,12502367,0,,P14416,,,,,1,0,1,0,1,0
64131,Literature-derived,In vitro displacement from Dopamine receptor D2,"Title: Novel selective and partial agonists of 5-HT3 receptors. Part 1. Synthesis and biological evaluation of piperazinopyrrolothienopyrazines._||_Abstract: A series of piperazinopyrrolo[1,2-a]thieno[3,2-e]- and -[2,3-e]pyrazine derivatives were prepared and evaluated in order to determine the necessary requirements for high affinity on the 5-HT3 receptors and high selectivity versus other 5-HT receptor subtypes. Various substitutions on the piperazine and the thiophene ring of the pyrrolothienopyrazine moieties were systematically explored as well as replacement of the piperazine by other cyclic amines. The best compounds are in the nanomolar range of affinity of 5-HT3 receptors with high to very high selectivity (up to 10,000 for 14b). These high-affinity compounds have in common a benzyl- or allylpiperazine substituent with no substitutions on the thiophene ring. Five of these compounds (1a, 4b, 13a,b, and 14b) have been evaluated on the Von Bezold-Jarisch reflex and were characterized as partial agonists. One of them, 13a, has shown in vivo at very low dose a potent anxiolytic-like activity in the light/dark test.",43,ChEMBL,CHEMBL671347,20181015,9863146,103237550,1813,In vitro,P14416,Curation Efforts|Research and Development,8642566,0,,P14416,,,,,1,0,1,0,0,0
64132,Literature-derived,In vitro displacement from Dopamine receptor D2,"Title: Novel selective and partial agonists of 5-HT3 receptors. Part 1. Synthesis and biological evaluation of piperazinopyrrolothienopyrazines._||_Abstract: A series of piperazinopyrrolo[1,2-a]thieno[3,2-e]- and -[2,3-e]pyrazine derivatives were prepared and evaluated in order to determine the necessary requirements for high affinity on the 5-HT3 receptors and high selectivity versus other 5-HT receptor subtypes. Various substitutions on the piperazine and the thiophene ring of the pyrrolothienopyrazine moieties were systematically explored as well as replacement of the piperazine by other cyclic amines. The best compounds are in the nanomolar range of affinity of 5-HT3 receptors with high to very high selectivity (up to 10,000 for 14b). These high-affinity compounds have in common a benzyl- or allylpiperazine substituent with no substitutions on the thiophene ring. Five of these compounds (1a, 4b, 13a,b, and 14b) have been evaluated on the Von Bezold-Jarisch reflex and were characterized as partial agonists. One of them, 13a, has shown in vivo at very low dose a potent anxiolytic-like activity in the light/dark test.",43,ChEMBL,CHEMBL878134,20181015,9863146,103237550,1813,In vitro,P14416,Curation Efforts|Research and Development,8642566,0,,P14416,,,,,1,0,1,0,0,0
64133,Literature-derived,Inhibitory activity against Dopamine receptor D2 using [3H]-spiperone as radioligand at 10e-5 M concentration,"Title: Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut._||_Abstract: A series of benzoxazoles with a nitrogen-containing heterocyclic substituent at the 2-position was prepared and evaluated for 5-HT3 partial agonist activity on isolated guinea pig ileum. The nature of the substituent at the 5-position of the benzoxazole ring affected the potency for the 5-HT3 receptor, and the 5-chloro derivatives showed increased potency and lowered intrinsic activity. 5-Chloro-7-methyl-2-(4-methyl-1-homopiperazinyl)benzoxazole (6v) exhibited a high binding affinity in the same range as that of the 5-HT3 antagonist granisetron, and its intrinsic activity was 12% of that of 5-HT. Compound 6v inhibited 5-HT-evoked diarrhea but did not prolong the transition time of glass beads in the normal distal colon even at a dose of 100 times the ED50 for diarrhea inhibition in mice. Compounds of this type are expected to be effective for the treatment of irritable bowel syndrome without the side effect of constipation.",43,ChEMBL,CHEMBL873647,20181015,9795675,103319444,1813,,P14416,Curation Efforts|Research and Development,9685241,0,,P14416,,,,,1,0,1,0,1,0
64134,Literature-derived,Intrinsic activity was Determined,"Title: Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands._||_Abstract: Conformational and molecular mechanics studies of a new series of tricyclic ligands with affinity for either the dopamine D2 receptor or the 5-HT1A receptor, or both, has enabled us to elaborate considerably on previous pharmacophore models for these receptors. The new tricyclic ligands are either angular, 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives, or linear, 2,3,3a,4,5,9a-hexahydro-1H-benz[f]indole derivatives; they have either cis or trans ring junctions, and many of the ligands are resolved. In order to have X-ray crystal coordinates for every structural type, two additional crystal structures were determined: 14a, the trans-(+-)-6-hydroxy-3-(n-propyl) angular derivative as the hydrochloride, and (+-)-1,2,2a,3,4,8b-hexahydro-8-methoxy-2-(2-propenyl)-naphth[2,1- b]azetidine hydrochloride (16d). Several recently reported imidazoquinolinones with dopaminergic and serotonergic activities were also used in developing the models as were other known ligands which are conformationally constrained. A new method for determining intrinsic activity at the D2 receptor made consistent and reliable estimates of dopamine agonist, partial agonist, and antagonist activities available. The models explain these activities in terms of the 3-dimensional structural features of the ligands and their probable orientations at the D2 receptor site. They also explain why allyl and propyl analogs of some structures have very different affinities while affinities are quite similar for allyl and propyl analogs of other structures; at both receptors a particular orientation of the amine substituent in the binding site correlates with preference for allyl over propyl derivatives. Suggestions are made for enhancing selectivity at the 5-HT1A receptor or at the dopamine D2 receptor. An angular, cis, (3aR,9bS), 2-propyl, 9-hydroxy, 3-(n-propyl) analog should be selective for the 5-HT1A receptor. A linear, trans, (3aR,9aS), 7-hydroxy, 1-(2-propenyl) analog should be selective for the dopamine D2 receptor, and would be predicted to be an antagonist.",43,ChEMBL,CHEMBL670778,20181013,10014136|14944884,103193992|103194293,1813,,P14416,Curation Efforts|Research and Development,8496900,0,,P14416,,,,,1,0,1,0,1,0
64308,Confirmatory,In vitro binding affinity at human cloned Dopamine receptor D2A measured by ability to displace [3H]raclopride from D2A receptor expressed in mouse fibroblast (LtK-) cells,"Title: Synthesis of novel 5-substituted 3-amino-3,4-dihydro-2H-1-benzopyran derivatives and their interactions with the 5-HT1A receptor._||_Abstract: A series of new enantiomerically pure 3-amino-3,4-dihydro-2H-1-benzopyrans (3-aminochromans) has been synthesized from (R)- and (S)-5-methoxy-3-amino-3,4-dihydro-2H-1-benzopyran. The absolute configuration of the respective (R)- and (S)-enantiomers was deduced from X-ray crystallography of (R)-3-(N-isopropylamino)-5-methoxy-3,4-dihydro-2H-1-benzopyran, (R)-9a. Various 5-substituents were introduced via palladium-catalyzed carbonylation of N-substituted 3-amino-5-trifluoromethanesulfonyloxy-3,4-dihydro-2H-1-benzopyran. The effect of N- and 5-substitution on affinity for the 5-HT1A receptor was evaluated in competition experiments using rat hippocampal membranes and [3H]8-OH-DPAT as radioligand. Selected compounds were also tested for their affinity to the D1 (rat striatum), D2 (rat striatum), D2A (human cloned), and 5-HT2A (rat cortex) receptors. The intrinsic activity of the compounds was evaluated by measuring their effect on VIP-stimulated cAMP production in GH4ZD10 cells stably transfected with the 5-HT1A receptor. High-affinity compounds with high selectivity for the 5-HT1A receptor were found among structures substituted with carboxylate esters, amides, and ketones in the 5-position. Primary and secondary amines bound with lower affinity than tertiary amines. Larger substituents were well-tolerated by the receptor, but the smaller N-ethyl-N-isopropyl bound with lower affinity. Generally, the (R)-enantiomers displayed higher affinity for the 5-HT1A receptor than the corresponding (S)-enantiomers. In the present series of compounds, both full and partial agonists were found.",43,ChEMBL,CHEMBL670882,20181016,9797080|10084845|10537661|10585771|10591665|10639290|10679285|10685957|10709505|10850084,160693404|163319371|163322730|163333248|163333249|194137917|194151634|194165574|194172326|194172447,1813,In vitro,P14416,Curation Efforts|Research and Development,10956192,0,,P14416,9606.0,,,,1,0,1,0,0,0
64313,Confirmatory,In vitro binding affinity at human cloned Dopamine receptor D2A by measuring its ability to displace [3H]raclopride from D2A receptor expressed in mouse fibroblast (LtK-) cells,"Title: Synthesis of novel 5-substituted 3-amino-3,4-dihydro-2H-1-benzopyran derivatives and their interactions with the 5-HT1A receptor._||_Abstract: A series of new enantiomerically pure 3-amino-3,4-dihydro-2H-1-benzopyrans (3-aminochromans) has been synthesized from (R)- and (S)-5-methoxy-3-amino-3,4-dihydro-2H-1-benzopyran. The absolute configuration of the respective (R)- and (S)-enantiomers was deduced from X-ray crystallography of (R)-3-(N-isopropylamino)-5-methoxy-3,4-dihydro-2H-1-benzopyran, (R)-9a. Various 5-substituents were introduced via palladium-catalyzed carbonylation of N-substituted 3-amino-5-trifluoromethanesulfonyloxy-3,4-dihydro-2H-1-benzopyran. The effect of N- and 5-substitution on affinity for the 5-HT1A receptor was evaluated in competition experiments using rat hippocampal membranes and [3H]8-OH-DPAT as radioligand. Selected compounds were also tested for their affinity to the D1 (rat striatum), D2 (rat striatum), D2A (human cloned), and 5-HT2A (rat cortex) receptors. The intrinsic activity of the compounds was evaluated by measuring their effect on VIP-stimulated cAMP production in GH4ZD10 cells stably transfected with the 5-HT1A receptor. High-affinity compounds with high selectivity for the 5-HT1A receptor were found among structures substituted with carboxylate esters, amides, and ketones in the 5-position. Primary and secondary amines bound with lower affinity than tertiary amines. Larger substituents were well-tolerated by the receptor, but the smaller N-ethyl-N-isopropyl bound with lower affinity. Generally, the (R)-enantiomers displayed higher affinity for the 5-HT1A receptor than the corresponding (S)-enantiomers. In the present series of compounds, both full and partial agonists were found.",43,ChEMBL,CHEMBL670887,20181016,10564353,194137916,1813,In vitro,P14416,Curation Efforts|Research and Development,10956192,0,,P14416,10116.0,,,,1,0,1,0,0,0
64321,Confirmatory,Effective concentration was determined as thymidine uptake in CHO-L6 cells transfected with the rat Dopamine receptor D2L by mitogenesis assay (intrinsic activity),"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL672520,20181016,54562,103543557,1813,,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,,,,1,0,1,0,1,0
64334,Confirmatory,Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells,"Title: Cyanoindole derivatives as highly selective dopamine D(4) receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments._||_Abstract: Traceless linking of diethoxymethyl (DEM)-protected 5- and 6-cyanoindoles and subsequent incorporation of phenylpiperazine derivatives led to the 2- and 3-piperazinylmethyl-substituted cyanoindoles 3a-m. Dopamine receptor binding studies on the final products 3a-m clearly indicated strong and selective recognition of the D(4) subtype which is known as a promising target for the treatment of neuropsychiatric disorders. The most interesting binding properties were observed for the 2-aminomethyl-5-cyanoindoles FAUC 299 (3f) and FAUC 316 (3j) (K(i) = 0.52 and 1.0 nM, respectively) when the fluoro derivative 3j proved extraordinary selectivity over D(1), D(2long), D(2short), and D(3) (>8600). To determine ligand efficacy, mitogenesis experiments were performed indicating partial agonist effects for the test compounds 3f,j (35% and 30%, when compared to the full agonist quinpirole).",43,ChEMBL,CHEMBL672383,20181016,9908125|9995904|10314824|10498094|10567430|10594054|10641637|10643780|10663221|10665598|10830557|10831735|10833953|135398737,103165765|103381260|103381287|103381291|103381316|103381317|103381318|103381319|103381320|103381340|103381341|103381373|103381374|103381410,1813,,P14416,Curation Efforts|Research and Development,11087581,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
64335,Confirmatory,Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.,"Title: Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists._||_Abstract: Starting from dopamine receptor ligand BP897, an interactive drug discovery process leading to heterocyclic bioisosteres is demonstrated. The four step strategy involved a careful optimization of geometric and electronic properties by systematic modification of the attachment points and heteroatoms, respectively. Efficacy tuning by modification of the phenyl substituents led to both D3 partial agonists and full antagonists. The benzothiophenes 3c (FAUC346) and 3d (FAUC365) revealed outstanding D3 affinity and subtype selectivity.",43,ChEMBL,CHEMBL672384,20181017,3038495|9888555|9980998|10053476|10092819|10276451|10436653|10476504|10862425|10884046|10895106|11036640|11036641|11057969|11068912|11133602|44360984|44360992|44361021,103194907|103252954|103356181|103381106|103381310|103381311|103381506|103381577|103381657|103381658|103381661|103381662|103381925|103381942|103381944|103381963|103381993|103382091|103382409,1813,,P14416,Curation Efforts|Research and Development,12361386,0,,P14416,,,,,1,0,1,0,1,0
64482,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human Dopamine receptor D2L expressed in CHO cells,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL673085,20180930,10247719,103677635,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
64490,Confirmatory,in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]-0437 as radioligand.,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL671516,20181016,10590717|10780928,103345940|103346651,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64491,Confirmatory,in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]NPA as radioligand.,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL671517,20181016,9904074|10220541|10637198,103345942|103345968|103345969,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64492,Confirmatory,in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]spiperone as radioligand.,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL872883,20181016,10590717|10780928,103345940|103346651,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64493,Confirmatory,in vitro low binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]-spiperone as radioligand.,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL671518,20181016,119570,103245538,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64496,Literature-derived,in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]NPA as radioligand; NA is not determined,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL671521,20181016,119570,103245538,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64497,Literature-derived,in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]spiperone as radioligand; ND is not determined,"Title: Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists._||_Abstract: The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5, 4-f]-[1]benzopyran (12) and 6-amino-2-(N, N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D(3) receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D(2) receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.",43,ChEMBL,CHEMBL672500,20181016,9904074|10220541|10637198,103345942|103345968|103345969,1813,In vitro,P14416,Curation Efforts|Research and Development,11000009,0,,P14416,,198.0,,,1,0,1,0,1,0
64662,Confirmatory,Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.,"Title: Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists._||_Abstract: Starting from dopamine receptor ligand BP897, an interactive drug discovery process leading to heterocyclic bioisosteres is demonstrated. The four step strategy involved a careful optimization of geometric and electronic properties by systematic modification of the attachment points and heteroatoms, respectively. Efficacy tuning by modification of the phenyl substituents led to both D3 partial agonists and full antagonists. The benzothiophenes 3c (FAUC346) and 3d (FAUC365) revealed outstanding D3 affinity and subtype selectivity.",43,ChEMBL,CHEMBL672573,20181017,3038495|9888555|9980998|10053476|10092819|10276451|10436653|10476504|10862425|10884046|10895106|11036640|11036641|11057969|11068912|11133602|44360984|44360992|44361021,103194907|103252954|103356181|103381106|103381310|103381311|103381506|103381577|103381657|103381658|103381661|103381662|103381925|103381942|103381944|103381963|103381993|103382091|103382409,1813,,P14416,Curation Efforts|Research and Development,12361386,0,,P14416,,,,,1,0,1,0,1,0
64666,Confirmatory,Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells,"Title: Cyanoindole derivatives as highly selective dopamine D(4) receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments._||_Abstract: Traceless linking of diethoxymethyl (DEM)-protected 5- and 6-cyanoindoles and subsequent incorporation of phenylpiperazine derivatives led to the 2- and 3-piperazinylmethyl-substituted cyanoindoles 3a-m. Dopamine receptor binding studies on the final products 3a-m clearly indicated strong and selective recognition of the D(4) subtype which is known as a promising target for the treatment of neuropsychiatric disorders. The most interesting binding properties were observed for the 2-aminomethyl-5-cyanoindoles FAUC 299 (3f) and FAUC 316 (3j) (K(i) = 0.52 and 1.0 nM, respectively) when the fluoro derivative 3j proved extraordinary selectivity over D(1), D(2long), D(2short), and D(3) (>8600). To determine ligand efficacy, mitogenesis experiments were performed indicating partial agonist effects for the test compounds 3f,j (35% and 30%, when compared to the full agonist quinpirole).",43,ChEMBL,CHEMBL672577,20181016,9908125|9995904|10314824|10498094|10567430|10594054|10641637|10643780|10663221|10665598|10830557|10831735|10833953,103381260|103381287|103381291|103381316|103381317|103381318|103381319|103381320|103381340|103381341|103381373|103381374|103381410,1813,,P14416,Curation Efforts|Research and Development,11087581,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
64667,Confirmatory,Competitive binding affinity against human Dopamine receptor D2S by displacing [3H]spiperone from CHO cells,"Title: Cyanoindole derivatives as highly selective dopamine D(4) receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments._||_Abstract: Traceless linking of diethoxymethyl (DEM)-protected 5- and 6-cyanoindoles and subsequent incorporation of phenylpiperazine derivatives led to the 2- and 3-piperazinylmethyl-substituted cyanoindoles 3a-m. Dopamine receptor binding studies on the final products 3a-m clearly indicated strong and selective recognition of the D(4) subtype which is known as a promising target for the treatment of neuropsychiatric disorders. The most interesting binding properties were observed for the 2-aminomethyl-5-cyanoindoles FAUC 299 (3f) and FAUC 316 (3j) (K(i) = 0.52 and 1.0 nM, respectively) when the fluoro derivative 3j proved extraordinary selectivity over D(1), D(2long), D(2short), and D(3) (>8600). To determine ligand efficacy, mitogenesis experiments were performed indicating partial agonist effects for the test compounds 3f,j (35% and 30%, when compared to the full agonist quinpirole).",43,ChEMBL,CHEMBL672578,20181016,135398737,103165765,1813,,P14416,Curation Efforts|Research and Development,11087581,0,,P14416,,197.0,,,1,0,1,0,0,0
64793,Confirmatory,In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells,Title: Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)._||_Abstract: Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM). Mitogenesis experiments indicated partial agonist properties (42%). EPC syntheses of the target compounds of type 4 were performed starting from alpha-amino acids.,43,ChEMBL,CHEMBL675128,20180930,10247719,103677635,1813,In vitro,P14416,Curation Efforts|Research and Development,11549463,0,,P14416,,197.0,,,1,0,1,0,0,0
64796,Confirmatory,Effective concentration for Dopamine receptor D3 was determined,"Title: N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands._||_Abstract: The dopamine D(3) receptor is recognized as a potential therapeutic target for the treatment of various neurological and psychiatric disorders. Targetting high affinity and D(3) versus D(2) receptor-preferring ligands, the partial agonist BP 897 was taken as a lead structure. Variations in the spacer and the aryl moiety led to N-alkylated 1-(2-methyoxyphenyl)piperazines with markedly improved affinity and selectivity. Molecular modeling studies supported the structural development. Pharmacophore models for dopamine D(2) and D(3) receptor ligands were developed from their potentially bioactive conformation and were compared in order to get insight into molecular properties of importance for D(2)/D(3) receptor selectivity. For the 72 compounds presented here, an extended and more linear conformation in the aliphatic or aryl spacers turned out to be crucial for dopamine D(3) receptor selectivity. Structural diversity in the aryl moiety (benzamides, heteroarylamides, arylimides) had a major influence on (sub)nanomolar D(3) receptor affinity, which was optimized with more rigid aryl acrylamide derivatives. Compound 38 (ST 280, (E)-4-iodo-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)cinnamoylamide) displayed a most promising pharmacological profile (K(i) (hD(3)) = 0.5 nM; K(i) (hD(2L)) = 76.4 nM; selectivity ratio of 153), and above that, compound 38 offered the prospect of a novel radioligand as a pharmacological tool for various D(3) receptor-related in vitro and in vivo investigation.",43,ChEMBL,CHEMBL675130,20181017,44350888|44351005,103359567|103359830,1813,,P14416,Curation Efforts|Research and Development,12930150,0,,P14416,9527.0,,,,1,0,1,0,0,0
64797,Literature-derived,Intrinsic activity for Dopamine receptor D3 was determined,"Title: N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands._||_Abstract: The dopamine D(3) receptor is recognized as a potential therapeutic target for the treatment of various neurological and psychiatric disorders. Targetting high affinity and D(3) versus D(2) receptor-preferring ligands, the partial agonist BP 897 was taken as a lead structure. Variations in the spacer and the aryl moiety led to N-alkylated 1-(2-methyoxyphenyl)piperazines with markedly improved affinity and selectivity. Molecular modeling studies supported the structural development. Pharmacophore models for dopamine D(2) and D(3) receptor ligands were developed from their potentially bioactive conformation and were compared in order to get insight into molecular properties of importance for D(2)/D(3) receptor selectivity. For the 72 compounds presented here, an extended and more linear conformation in the aliphatic or aryl spacers turned out to be crucial for dopamine D(3) receptor selectivity. Structural diversity in the aryl moiety (benzamides, heteroarylamides, arylimides) had a major influence on (sub)nanomolar D(3) receptor affinity, which was optimized with more rigid aryl acrylamide derivatives. Compound 38 (ST 280, (E)-4-iodo-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)cinnamoylamide) displayed a most promising pharmacological profile (K(i) (hD(3)) = 0.5 nM; K(i) (hD(2L)) = 76.4 nM; selectivity ratio of 153), and above that, compound 38 offered the prospect of a novel radioligand as a pharmacological tool for various D(3) receptor-related in vitro and in vivo investigation.",43,ChEMBL,CHEMBL675131,20200703,44350852|44350888|44351005,103359465|103359567|103359830,1813,,P14416,Curation Efforts|Research and Development,12930150,0,,P14416,9527.0,,,,1,0,1,0,0,0
227608,Literature-derived,Intrinsic activity against dopamine D 2 receptor,"Title: Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands._||_Abstract: Conformational and molecular mechanics studies of a new series of tricyclic ligands with affinity for either the dopamine D2 receptor or the 5-HT1A receptor, or both, has enabled us to elaborate considerably on previous pharmacophore models for these receptors. The new tricyclic ligands are either angular, 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives, or linear, 2,3,3a,4,5,9a-hexahydro-1H-benz[f]indole derivatives; they have either cis or trans ring junctions, and many of the ligands are resolved. In order to have X-ray crystal coordinates for every structural type, two additional crystal structures were determined: 14a, the trans-(+-)-6-hydroxy-3-(n-propyl) angular derivative as the hydrochloride, and (+-)-1,2,2a,3,4,8b-hexahydro-8-methoxy-2-(2-propenyl)-naphth[2,1- b]azetidine hydrochloride (16d). Several recently reported imidazoquinolinones with dopaminergic and serotonergic activities were also used in developing the models as were other known ligands which are conformationally constrained. A new method for determining intrinsic activity at the D2 receptor made consistent and reliable estimates of dopamine agonist, partial agonist, and antagonist activities available. The models explain these activities in terms of the 3-dimensional structural features of the ligands and their probable orientations at the D2 receptor site. They also explain why allyl and propyl analogs of some structures have very different affinities while affinities are quite similar for allyl and propyl analogs of other structures; at both receptors a particular orientation of the amine substituent in the binding site correlates with preference for allyl over propyl derivatives. Suggestions are made for enhancing selectivity at the 5-HT1A receptor or at the dopamine D2 receptor. An angular, cis, (3aR,9bS), 2-propyl, 9-hydroxy, 3-(n-propyl) analog should be selective for the 5-HT1A receptor. A linear, trans, (3aR,9aS), 7-hydroxy, 1-(2-propenyl) analog should be selective for the dopamine D2 receptor, and would be predicted to be an antagonist.",43,ChEMBL,CHEMBL872123,20181013,47811|122334|6604756|9882257|10014056|10014057|10105311|10105844|10332127|10355219|10377224|10466962|14944887|18988817|18988835|22849991|22849992|44266612|44266623|44266636|44266651|44266689|44274687|44274739|44275015|44275135|44275155|44275362|44275604|44275615|44275616|44275766,103170221|103170246|103170275|103170310|103170342|103170445|103171763|103171824|103171864|103171983|103175300|103193583|103193697|103193716|103193719|103193873|103194077|103194161|103194373|103194409|103194492|103194647|103194729|103194863|103195296|103195323|103195324|103195613|103195643|103244512|103700484|163333467,1813,,P14416,Curation Efforts|Research and Development,8496900,0,,P14416,10029.0,,,,1,0,1,0,1,0
230928,Literature-derived,Ratio of the binding affinity to low affinity state (D2 low) to high affinity state (D2 high),"Title: New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans._||_Abstract: A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high- and low-affinity agonist states (D2High and D2Low, respectively) of the dopamine (DA) D2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D2High receptor vs the 5HT1A and alpha 1 receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D2High receptor vs the alpha 1 and 5HT1A receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D2 agonist pharmacophoric criteria and was proposed as the D2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo- and hyperdopaminergic activity, without the side effects associated with complete D2 agonism or antagonism.",43,ChEMBL,CHEMBL850077,20200704,5374|148841|5311189|9927497|9949399|19432941|19432943|19432944|19432945|21479400|21479403|21479410|21479414|21479415|21479416|44355694|44355710|44355732|44355761|44355918|44355919|44355928|44355929|44355935|44355973|44355978|44355989|44355995|44356007|44356019|44356048|44356061|44356068|44356069|44356070|44356093|44356120|44356121|44356132|44356133|44356141|44356251|44356252|44356265|44356267|44356275|44356279|44356285|44356290|44356294|44356303|44356304|44356323|44356329|44356330|44356524|44356533|45262004|45262088|45265212,103166191|103185398|103370717|103370718|103370719|103370745|103370775|103370812|103371055|103371056|103371058|103371082|103371083|103371092|103371110|103371111|103371119|103371141|103371150|103371158|103371175|103371231|103371243|103371253|103371276|103371278|103371280|103371281|103371334|103371335|103371356|103371358|103371390|103371391|103371405|103371406|103371430|103371633|103371644|103371645|103371668|103371670|103371691|103371693|103371698|103371710|103371720|103371727|103371738|103371739|103371765|103371776|103371777|103371816|103372115|103372146|103372148|103673437|103673549|103678351,1813,,P14416,Curation Efforts|Research and Development,9435894,0,,P14416,,,,,1,0,1,0,1,0
231448,Literature-derived,"Ratio D2 partial agonist, Ki(D2 Low)/Ki(D2 High), to compare a compounds estimated intrinsic activity.",Title: New generation dopaminergic agents. Part 8: heterocyclic bioisosteres that exploit the 7-OH-2-(aminomethyl)chroman D(2) template._||_Abstract: Based on the 7-OH-2-(aminomethyl)chroman dopamine D(2) template (2) is described the preparation and resolution of two bioisosteric analogues. The benzimidazol-2-one derivative (6) had similar affinity to the known indolone derivative (4).,43,ChEMBL,CHEMBL850886,20200630,9820313|9861459|9948584|10063875|10378389|10470579|10613605,103251600|103251614|103253086|103302677|103302704|103302710|103302711,1813,,P14416,Curation Efforts|Research and Development,11814775,0,,P14416,,,,,0,1,0,1,0,0
238944,Confirmatory,Inhibition of [3H]YM-09151-2 binding to human Dopamine D2 receptor expressed in CHO cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL876373,20181018,3038495,103194907,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
238970,Confirmatory,Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL828890,20181018,9826580|9887463|9891901|9980998|10001256|10276451|10436285|11223885|11224283|11307083|11316847|11351639|11408148|11477180|44309509|44309510|44309688|44309775,103252206|103252237|103252954|103265393|103265394|103265757|103265819|103265880|103265882|103265917|103381942|103440227|103440257|103440349|103440417|103463820|103463979|103464153,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
238971,Confirmatory,Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL828891,20181018,9826580|9887463|9891901|9980998|10001256|10276451|10436285|11223885|11224283|11307083|11316847|11351639|11408148|11477180|44309509|44309510|44309688|44309775,103252206|103252237|103252954|103265393|103265394|103265757|103265819|103265880|103265882|103265917|103381942|103440227|103440257|103440349|103440417|103463820|103463979|103464153,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
239043,Confirmatory,Inhibition of [125I]iodosulpiride binding to human Dopamine D2 receptor expressed in CHO cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL829065,20181018,9828617,103528188,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
239060,Confirmatory,Inhibition of [125I]iodosulpiride binding to human Dopamine D2L receptor expressed in CHO cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL876379,20181018,5311096,103291265,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
252264,Literature-derived,Intrinsic activity at Dopamine receptor D2 in CHO cells,Title: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,43,ChEMBL,CHEMBL826715,20181018,9826580,103265819,1813,,P14416,Curation Efforts|Research and Development,15916415,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
259994,Confirmatory,Binding affinity to dopamine receptor D2,"Title: Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists._||_Abstract: A series of pyrrolizidine esters, amides, and ureas was prepared and tested for 5-HT(4) and 5-HT(3) receptor binding, 5-HT(4) receptor agonism in the rat tunica muscularis mucosae (TMM) assay, and for 5-HT(3) receptor-mediated functional antagonism in the Bezold-Jarisch reflex assay. Several pyrrolizidine derivatives were identified with high affinity for the 5-HT(4) receptor, including benzamide 12a (SC-53116), a potent and selective 5-HT(4) partial agonist that exhibits efficacy in promoting antral contractions and activity in promoting gastric emptying in canine models. Also discovered were 5-HT(4) receptor antagonists, including imidazopyridine amide 12h (SC-53606), which is a potent and selective 5-HT(4) receptor antagonist with a pA(2) value of 8.13 in the rat TMM assay. N-Methyl indole ester 13d was identified as a potent 5-HT(4) antagonist with a pA(2) value of 8.93. High selectivity was observed for these pyrrolizidine derivatives versus other monoamine receptors, including 5-HT(1), 5-HT(2), D(1), D(2), alpha(1), alpha(2), and beta receptors.",43,ChEMBL,CHEMBL858805,20181020,2769|132337|133999|9906777|11493559|11493794|11508052|11522273|15095973|44407083,103210742|103210855|103478028|103478143|103478257|103478352|103478363|103478414|123090165|174520176,1813,,P14416,Curation Efforts|Research and Development,16451077,0,,P14416,9606.0,,,,1,0,1,0,1,0
265123,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL871242,20181020,10403608|11983282|17449900|17469721|17475863|25333445|41532205|44300865|44412182|44412191|44412268|44412269|44412458|44412468|44412482|44412494,103246744|103489734|103489735|103489766|103489767|103489981|103489982|103490064|103490098|103490441|103490442|103490471|103490503|103490529|103490530|103490557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265124,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL871243,20181020,10403608|11983282|17449900|17469721|17475863|25333445|41532205|44300865|44412182|44412191|44412268|44412269|44412458|44412468|44412482|44412494,103246744|103489734|103489735|103489766|103489767|103489981|103489982|103490064|103490098|103490441|103490442|103490471|103490503|103490529|103490530|103490557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265128,Literature-derived,Intrinsic activity against dopamine D2(long) receptor assessed as [3H]thymidine uptake in CHO cells relative to quinpirole by mitogenesis assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL870761,20181020,11983282|17449900,103489734|103490441,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265129,Confirmatory,Intrinsic activity against dopamine D2(long) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL871223,20181020,54562|11983282|17449900,103489734|103490441|103543557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265130,Literature-derived,Intrinsic activity against dopamine D2(long) receptor expressed in CHO cells relative to quinpirole by GTPgammaS assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL859986,20181020,11983282|17449900,103489734|103490441,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265131,Confirmatory,Intrinsic activity against dopamine D2(long) receptor expressed in CHO cells by GTPgammaS assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL871313,20181020,54562|11983282,103490441|103543557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265132,Literature-derived,Intrinsic activity against dopamine D2(short) receptor assessed as [3H]thymidine uptake in CHO cells relative to quinpirole by mitogenesis assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL859987,20181020,11983282|17449900,103489734|103490441,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265133,Confirmatory,Intrinsic activity against dopamine D2(short) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL859988,20181020,54562|11983282|17449900,103489734|103490441|103543557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265134,Literature-derived,Intrinsic activity against dopamine D2(short) receptor expressed in CHO cells relative to quinpirole by GTPgammaS assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL859989,20181020,11983282|17449900,103489734|103490441,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
265135,Confirmatory,Intrinsic activity against dopamine D2(short) receptor expressed in CHO cells by GTPgammaS assay,"Title: Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype._||_Abstract: Aminomethyl-substituted biaryls bearing a pyrazole or triazole moiety were synthesized and investigated for dopamine and serotonin receptor binding. The N-arylpyrazoles 3b,f,g and 4 revealed Ki values in the subnanomolar range (0.28-0.70 nM) for the dopamine D4 receptor subtype. Employing both mitogenesis and GTPgammaS assays, ligand efficacy was evaluated indicating partial agonist properties. Interestingly, the tetrahydropyrimidine 4 (FAUC 2020) displayed significant intrinsic selectivity for D2(long) over D2(short).",43,ChEMBL,CHEMBL859990,20181020,54562|11983282,103490441|103543557,1813,,P14416,Curation Efforts|Research and Development,16563764,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
266773,Confirmatory,Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane,"Title: 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist._||_Abstract: A series of novel 2-[(4-phenylpiperazin-1-yl)methyl]imidazoazines and aza-analogues were prepared and screened at selected dopamine, serotonin, and adrenergic receptor subtypes. 2-Substituted imidazopyridines and pyridazines presented high affinities and selectivities for D4 dopamine receptors. Whereas functional experiments indicated neutral antagonists or weak partial agonist effects for most of the target compounds, the 2-methoxyphenyl substituted 2-piperazinylmethylimidazopyridine 3c (PIP3EA) displayed substantial agonist efficacy in mitogenesis experiments and GTPgammaS binding tests, resulting in EC50 values of 3.0 (46%) and 4.5 nM (57%), respectively. Our D4 agonist 3c induced penile erection in vivo when administered to rats. This effect was inhibited by L-745,870 a D4 selective antagonist, confirming the mechanistic pathway.",43,ChEMBL,CHEMBL866799,20181020,1248739|6469693|6469918|9995904|10314824|10404144|11516033|11517928|11559581|11574902|11575799|11581237|11583188|11626748|11631892|11633170|11638780|11652518|11655570|11659604|11661609|11682812|11689612|11696910|11697270|135398737,103165765|103165864|103381320|103381341|103491174|103491176|103491203|103491204|103491205|103491234|103491260|103491261|103491262|103491290|103491321|103491326|103491351|103491540|103491563|103491590|103491622|103491623|103491674|103491675|103491676|103491677,1813,,P14416,Curation Efforts|Research and Development,16789750,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
266774,Confirmatory,Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane,"Title: 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist._||_Abstract: A series of novel 2-[(4-phenylpiperazin-1-yl)methyl]imidazoazines and aza-analogues were prepared and screened at selected dopamine, serotonin, and adrenergic receptor subtypes. 2-Substituted imidazopyridines and pyridazines presented high affinities and selectivities for D4 dopamine receptors. Whereas functional experiments indicated neutral antagonists or weak partial agonist effects for most of the target compounds, the 2-methoxyphenyl substituted 2-piperazinylmethylimidazopyridine 3c (PIP3EA) displayed substantial agonist efficacy in mitogenesis experiments and GTPgammaS binding tests, resulting in EC50 values of 3.0 (46%) and 4.5 nM (57%), respectively. Our D4 agonist 3c induced penile erection in vivo when administered to rats. This effect was inhibited by L-745,870 a D4 selective antagonist, confirming the mechanistic pathway.",43,ChEMBL,CHEMBL866800,20181020,1248739|6469693|6469918|9995904|10314824|10404144|11516033|11517928|11559581|11574902|11575799|11581237|11583188|11626748|11631892|11633170|11638780|11652518|11655570|11659604|11661609|11682812|11689612|11696910|11697270|135398737,103165765|103165864|103381320|103381341|103491174|103491176|103491203|103491204|103491205|103491234|103491260|103491261|103491262|103491290|103491321|103491326|103491351|103491540|103491563|103491590|103491622|103491623|103491674|103491675|103491676|103491677,1813,,P14416,Curation Efforts|Research and Development,16789750,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
266798,Confirmatory,Displacement of [3H]7-OH-DPAT from human dopamine receptor D2(long) in CHO cell membrane,"Title: 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist._||_Abstract: A series of novel 2-[(4-phenylpiperazin-1-yl)methyl]imidazoazines and aza-analogues were prepared and screened at selected dopamine, serotonin, and adrenergic receptor subtypes. 2-Substituted imidazopyridines and pyridazines presented high affinities and selectivities for D4 dopamine receptors. Whereas functional experiments indicated neutral antagonists or weak partial agonist effects for most of the target compounds, the 2-methoxyphenyl substituted 2-piperazinylmethylimidazopyridine 3c (PIP3EA) displayed substantial agonist efficacy in mitogenesis experiments and GTPgammaS binding tests, resulting in EC50 values of 3.0 (46%) and 4.5 nM (57%), respectively. Our D4 agonist 3c induced penile erection in vivo when administered to rats. This effect was inhibited by L-745,870 a D4 selective antagonist, confirming the mechanistic pathway.",43,ChEMBL,CHEMBL864789,20181020,6469693,103491262,1813,,P14416,Curation Efforts|Research and Development,16789750,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
266799,Confirmatory,Displacement of [3H]7-OH-DPAT from porcine dopamine receptor D2,"Title: 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist._||_Abstract: A series of novel 2-[(4-phenylpiperazin-1-yl)methyl]imidazoazines and aza-analogues were prepared and screened at selected dopamine, serotonin, and adrenergic receptor subtypes. 2-Substituted imidazopyridines and pyridazines presented high affinities and selectivities for D4 dopamine receptors. Whereas functional experiments indicated neutral antagonists or weak partial agonist effects for most of the target compounds, the 2-methoxyphenyl substituted 2-piperazinylmethylimidazopyridine 3c (PIP3EA) displayed substantial agonist efficacy in mitogenesis experiments and GTPgammaS binding tests, resulting in EC50 values of 3.0 (46%) and 4.5 nM (57%), respectively. Our D4 agonist 3c induced penile erection in vivo when administered to rats. This effect was inhibited by L-745,870 a D4 selective antagonist, confirming the mechanistic pathway.",43,ChEMBL,CHEMBL864790,20181020,6469693,103491262,1813,,P14416,Curation Efforts|Research and Development,16789750,0,,P14416,9823.0,,,,1,0,1,0,1,0
266800,Literature-derived,Activity at human dopamine receptor D2(short) expressed in CHOK1 cells assessed as stimulation of [35S]GTP-gammaS binding at 10 uM,"Title: 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist._||_Abstract: A series of novel 2-[(4-phenylpiperazin-1-yl)methyl]imidazoazines and aza-analogues were prepared and screened at selected dopamine, serotonin, and adrenergic receptor subtypes. 2-Substituted imidazopyridines and pyridazines presented high affinities and selectivities for D4 dopamine receptors. Whereas functional experiments indicated neutral antagonists or weak partial agonist effects for most of the target compounds, the 2-methoxyphenyl substituted 2-piperazinylmethylimidazopyridine 3c (PIP3EA) displayed substantial agonist efficacy in mitogenesis experiments and GTPgammaS binding tests, resulting in EC50 values of 3.0 (46%) and 4.5 nM (57%), respectively. Our D4 agonist 3c induced penile erection in vivo when administered to rats. This effect was inhibited by L-745,870 a D4 selective antagonist, confirming the mechanistic pathway.",43,ChEMBL,CHEMBL864278,20181020,6469693,103491262,1813,,P14416,Curation Efforts|Research and Development,16789750,0,,P14416,9606.0,198.0,,,1,0,1,0,1,0
267493,Confirmatory,Binding affinity to D2 receptor,"Title: (R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties._||_Abstract: Recent studies have suggested that the alpha7 nicotinic acetylcholine receptors play important roles in learning and memory. Herein, we describe our research of the structure-activity relationships (SAR) in a series of (S)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-ones bearing various bicyclic moieties to discover novel alpha7 receptor agonists. Through a number of SAR studies on the series, we have found out that inhibition of CYP 2D6 isozyme, which was a primary obstacle for the previously identified compound, was avoidable by the introduction of bicyclic moieties. Chemical optimization of the series led to the identification of a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist 23. This compound not only possessed high binding affinity (K(i) = 3 nmol/L) toward the alpha7 receptor but also showed agonistic activity even at a concentration of 0.1 micromol/L. In addition, compound 23 improved cognition in several rat models, which might suggest the potential of the alpha7 receptor partial agonist for the treatment of neurological disorders including cognitive dysfunction.",43,ChEMBL,CHEMBL869737,20181020,71450922,163316016,1813,,P14416,Curation Efforts|Research and Development,16821797,0,,P14416,9606.0,,,,1,0,1,0,0,0
274456,Confirmatory,Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane,"Title: Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction._||_Abstract: The goal of this study was to identify a structurally distinct D(4)-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl)piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.",43,ChEMBL,CHEMBL910434,20181021,6005|9861462|10425450|16094664|16094676|16094677|16094681|16094698|16094699,103167211|103503867|103503868|103503875|103503882|103503913|103503918|103503972|103503973,1813,,P14416,Curation Efforts|Research and Development,17149874,0,,P14416,9606.0,45.0,,,1,0,1,0,0,0
274501,Confirmatory,Binding affinity to human D2S receptor,"Title: Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction._||_Abstract: The goal of this study was to identify a structurally distinct D(4)-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl)piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.",43,ChEMBL,CHEMBL855643,20181021,9861462|16094676|16094677|16094681,103503882|103503913|103503972|103503973,1813,,P14416,Curation Efforts|Research and Development,17149874,0,,P14416,9606.0,,,,1,0,1,0,0,0
297330,Confirmatory,Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells,"Title: Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents._||_Abstract: Dopamine D3 receptor antagonists and partial agonists have been shown to modulate drug-seeking effects induced by cocaine and other abused substances. Compound 6 [PG01037, (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-4-pyridine-2-ylbenzamide)] and related analogues are currently being evaluated in animal models of drug addiction. In these studies, a discrepancy between in vitro binding affinity, in vivo occupancy, and behavioral potency has been observed. The purpose of this study was to examine (1) modifications of the 2-pyridylphenyl moiety of 6 and (2) hydroxyl, acetyl, and cyclopropyl substitutions on the butylamide linking chain systematically coupled with 2-fluorenylamide or 2-pyridylphenylamide and 2-methoxy- or 2,3-dichloro-substituted phenylpiperazines to measure the impact on binding affinity, D2/D3 selectivity, lipophilicity, and function. In general, these modifications were well tolerated at the human dopamine D3 (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays. Several analogues showed >100-fold selectivity for dopamine D3 over D2 and D4 receptors. In addition, while all the derivatives with an olefinic linker were antagonists, in quinpirole-stimulated mitogenesis at hD3 receptors, several of the hydroxybutyl-linked analogues (16, 17, 21) showed partial agonist activity. Finally, several structural modifications reduced lipophilicities while retaining the desired binding profile.",43,ChEMBL,CHEMBL895648,20181022,9826580|9891901|11477180|11676873|25141533|44309775|44427818|44427820|44427821|44427822|44427823|44427824|44427825|44427826|44427827|44427829|44427831|44427835|44427836|44427839|44427840|44427841|44427842,103252237|103265819|103265917|103440257|103472584|103526705|103526706|103526707|103526708|103526709|103526710|103526711|103526712|103526713|103526714|103526715|103526716|103526717|103526718|103526720|103526721|103526722|103526723,1813,,P14416,Curation Efforts|Research and Development,17672446,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
301641,Literature-derived,Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes at 100 nM,"Title: Click chemistry based solid phase supported synthesis of dopaminergic phenylacetylenes._||_Abstract: 'Click resins' enable solid phase supported reactions to work under nearly perfect conditions fulfilling the requirements of click chemistry. Utilizing the formylpyrrolylmethyltriazole (FPMT) linker 6, which is readily available via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), a BAL strategy could be successfully applied for a parallel synthesis of dopaminergic phenylacetylens. A focused library of 20 test compounds revealing three points of diversity was generated by a four-step SPOS approach including microwave assisted Sonogashira coupling. GPCR-ligand binding assays indicated excellent dopamine D3 and D4 receptor binding affinities which were identified to cause a partial agonist activity for the most potent test compounds 2c,e,i,k.",43,ChEMBL,CHEMBL898771,20181022,44436596|44436597|44436598|44436599|44436600|44436601|44436602|44436603|44436605|44436606|44436608|44436610|44436612|44436613|44436616|44436617|44436618|44436619|44436621|44436623,103543063|103543064|103543065|103543067|103543068|103543069|103543070|103543071|103543073|103543074|103543076|103543078|103543080|103543081|103543084|103543085|103543086|103543087|103543089|103543091,1813,,P14416,Curation Efforts|Research and Development,17827018,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
301642,Literature-derived,Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes at 100 nM,"Title: Click chemistry based solid phase supported synthesis of dopaminergic phenylacetylenes._||_Abstract: 'Click resins' enable solid phase supported reactions to work under nearly perfect conditions fulfilling the requirements of click chemistry. Utilizing the formylpyrrolylmethyltriazole (FPMT) linker 6, which is readily available via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), a BAL strategy could be successfully applied for a parallel synthesis of dopaminergic phenylacetylens. A focused library of 20 test compounds revealing three points of diversity was generated by a four-step SPOS approach including microwave assisted Sonogashira coupling. GPCR-ligand binding assays indicated excellent dopamine D3 and D4 receptor binding affinities which were identified to cause a partial agonist activity for the most potent test compounds 2c,e,i,k.",43,ChEMBL,CHEMBL898772,20181022,44436596|44436597|44436598|44436599|44436600|44436601|44436602|44436603|44436605|44436606|44436608|44436610|44436612|44436613|44436616|44436617|44436618|44436619|44436621|44436623,103543063|103543064|103543065|103543067|103543068|103543069|103543070|103543071|103543073|103543074|103543076|103543078|103543080|103543081|103543084|103543085|103543086|103543087|103543089|103543091,1813,,P14416,Curation Efforts|Research and Development,17827018,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
301655,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes,"Title: Click chemistry based solid phase supported synthesis of dopaminergic phenylacetylenes._||_Abstract: 'Click resins' enable solid phase supported reactions to work under nearly perfect conditions fulfilling the requirements of click chemistry. Utilizing the formylpyrrolylmethyltriazole (FPMT) linker 6, which is readily available via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), a BAL strategy could be successfully applied for a parallel synthesis of dopaminergic phenylacetylens. A focused library of 20 test compounds revealing three points of diversity was generated by a four-step SPOS approach including microwave assisted Sonogashira coupling. GPCR-ligand binding assays indicated excellent dopamine D3 and D4 receptor binding affinities which were identified to cause a partial agonist activity for the most potent test compounds 2c,e,i,k.",43,ChEMBL,CHEMBL898785,20181022,44436596|44436597|44436598|44436599|44436600|44436601|44436602|44436603|44436605|44436606|44436608|44436610|44436617|44436618|44436621,103543063|103543064|103543065|103543067|103543068|103543069|103543070|103543071|103543073|103543074|103543076|103543078|103543085|103543086|103543089,1813,,P14416,Curation Efforts|Research and Development,17827018,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
301656,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes,"Title: Click chemistry based solid phase supported synthesis of dopaminergic phenylacetylenes._||_Abstract: 'Click resins' enable solid phase supported reactions to work under nearly perfect conditions fulfilling the requirements of click chemistry. Utilizing the formylpyrrolylmethyltriazole (FPMT) linker 6, which is readily available via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), a BAL strategy could be successfully applied for a parallel synthesis of dopaminergic phenylacetylens. A focused library of 20 test compounds revealing three points of diversity was generated by a four-step SPOS approach including microwave assisted Sonogashira coupling. GPCR-ligand binding assays indicated excellent dopamine D3 and D4 receptor binding affinities which were identified to cause a partial agonist activity for the most potent test compounds 2c,e,i,k.",43,ChEMBL,CHEMBL898786,20181022,44436596|44436597|44436598|44436599|44436600|44436601|44436602|44436603|44436605|44436606|44436608|44436610|44436617|44436618|44436621,103543063|103543064|103543065|103543067|103543068|103543069|103543070|103543071|103543073|103543074|103543076|103543078|103543085|103543086|103543089,1813,,P14416,Curation Efforts|Research and Development,17827018,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
388667,Confirmatory,Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells,"Title: Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies._||_Abstract: Enynes of type 4 and 5 as long chain derivatives of the nonaromatic dopamine D 3 receptor agonist 3 (FAUC 73) were prepared by exploiting chemoselective functionalization of the azido-substituted vinyl triflate 9. Radioligand binding studies indicated excellent D 3 affinity and selectivity over related GPCRs for the terminal alkynes 4c (FAUC 460) and 5c. Biphasic displacement curves gave picomolar K i values for the high affinity binding site of D 3. According to mitogenesis experiments and bioluminescence based cAMP assays, the biphenylcarboxamide 4c and its click chemistry derived triazole analogue 5c behaved as strong partial agonists but relative ligand efficacy significantly depended on the type of functional assay. Site directed mutagenesis involving the mutants D 3 D3.32E, and D 3 F6.51W implied that ligand interactions with D3.32 and F6.51 are highly crucial, giving rise to analogous binding modes for dopamine, classical and enyne type agonists.",43,ChEMBL,CHEMBL995087,20181026,681|25139180|25139181|25139329|25139331|25139332|25139335|25139477|25139478|25139479|25139481,103167911|103646413|103646521|103646522|103646523|103646524|103646585|103646586|103646587|103646588|103646589,1813,,P14416,Curation Efforts|Research and Development,18834111,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
388668,Confirmatory,Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells,"Title: Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies._||_Abstract: Enynes of type 4 and 5 as long chain derivatives of the nonaromatic dopamine D 3 receptor agonist 3 (FAUC 73) were prepared by exploiting chemoselective functionalization of the azido-substituted vinyl triflate 9. Radioligand binding studies indicated excellent D 3 affinity and selectivity over related GPCRs for the terminal alkynes 4c (FAUC 460) and 5c. Biphasic displacement curves gave picomolar K i values for the high affinity binding site of D 3. According to mitogenesis experiments and bioluminescence based cAMP assays, the biphenylcarboxamide 4c and its click chemistry derived triazole analogue 5c behaved as strong partial agonists but relative ligand efficacy significantly depended on the type of functional assay. Site directed mutagenesis involving the mutants D 3 D3.32E, and D 3 F6.51W implied that ligand interactions with D3.32 and F6.51 are highly crucial, giving rise to analogous binding modes for dopamine, classical and enyne type agonists.",43,ChEMBL,CHEMBL995088,20181026,681|25139180|25139181|25139329|25139331|25139332|25139335|25139477|25139478|25139479|25139481,103167911|103646413|103646521|103646522|103646523|103646524|103646585|103646586|103646587|103646588|103646589,1813,,P14416,Curation Efforts|Research and Development,18834111,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
439360,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine D2long receptor expressed in CHO cells,"Title: 1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands._||_Abstract: On the basis of previous work on dopaminergic partial agonists of type 1 and 2, disubstituted ferrocenes are presented as valuable arene bioisosteres. Because substituents at the distal cyclopentadienyl ring are able to adjust the relative disposition that is required for ligand binding, disubstituted ferrocenes can act as molecular hinges. Taking advantage of click chemistry, the regioselective construction and functionalization of the target molecules is reported. Thus triazole derived appendages were used for the fine-tuning of biological activity and for the attachment of linker units generating bivalent GPCR ligands. Receptor binding was evaluated by radioligand displacement experiments, revealing superaffinity with sub- to single-digit nanomolar K(i) values for particular test compounds. As a neutral antagonist at the dopamine receptors D3 and D4 and a potent partial agonist at the D2 subtype (intrinsic activity = 57%, EC(50) = 2.5 nM), the bifunctional ferrocene 10b revealed a novel and unique activity profile.",43,ChEMBL,CHEMBL1059353,20180911,54562|45483654|45483655,103543557|103699198|103699199,1813,,P14416,Curation Efforts|Research and Development,19807103,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
439361,Confirmatory,Displacement of [3H]spiperone from human cloned dopamine D2short receptor expressed in CHO cells,"Title: 1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands._||_Abstract: On the basis of previous work on dopaminergic partial agonists of type 1 and 2, disubstituted ferrocenes are presented as valuable arene bioisosteres. Because substituents at the distal cyclopentadienyl ring are able to adjust the relative disposition that is required for ligand binding, disubstituted ferrocenes can act as molecular hinges. Taking advantage of click chemistry, the regioselective construction and functionalization of the target molecules is reported. Thus triazole derived appendages were used for the fine-tuning of biological activity and for the attachment of linker units generating bivalent GPCR ligands. Receptor binding was evaluated by radioligand displacement experiments, revealing superaffinity with sub- to single-digit nanomolar K(i) values for particular test compounds. As a neutral antagonist at the dopamine receptors D3 and D4 and a potent partial agonist at the D2 subtype (intrinsic activity = 57%, EC(50) = 2.5 nM), the bifunctional ferrocene 10b revealed a novel and unique activity profile.",43,ChEMBL,CHEMBL1059354,20180911,54562|45483654|45483655,103543557|103699198|103699199,1813,,P14416,Curation Efforts|Research and Development,19807103,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
448410,Confirmatory,Displacement of [3H]spiperone from D2 receptor,Title: Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia._||_Abstract: A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.,43,ChEMBL,CHEMBL1040200,20180911,3559|44626329|45486819|45486820|45486824|45486825|45486840|45486845|45486859|45486879|45486887|45486891|45486892|45486893|45486898|45486902|52941809|52946660|70693417,103167216|103706610|103706621|103706633|103706634|103706649|103706662|103706673|103706699|103706737|103706747|103706754|103706755|103706756|103706763|103706771|123085612|123094810|160697609,1813,,P14416,Curation Efforts|Research and Development,19720528,0,,P14416,,,,,1,0,1,0,0,0
450651,Confirmatory,Inhibition of dopamine D2 receptor,"Title: Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways._||_Abstract: A novel family of 1,3,5-trisubstituted 1,2,4-triazoles was discovered as potent and selective ligands for the delta opioid receptor by rational design. Compound 5b exhibited low-nanomolar in vitro binding affinity (IC(50)=5.8 nM), excellent selectivity for the delta opioid receptor over the alternative mu and kappa opioid receptors, full agonist efficacy in receptor down-regulation and MAP kinase activation assays, and low-efficacy partial agonist activity in stimulation of GTPgammaS binding. The apparent discrepancy observed in these functional assays may stem from different signaling pathways involved in each case, as found previously for other G-protein coupled receptors. More biological studies are underway to better understand the differential stimulation of signaling pathways by these novel compounds.",43,ChEMBL,CHEMBL1050444,20180911,11957735,103719014,1813,,P14416,Curation Efforts|Research and Development,19646882,0,,P14416,,,,,1,0,1,0,0,0
460127,Confirmatory,Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting,"Title: Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist._||_Abstract: A series of new aporphine analogues were synthesized and pharmacologically evaluated. 11-Allyloxy-(17), 11-propargyloxy-(20), and dihydrofuro-(19) aporphines displayed the highest affinity at the 5-HT(1A) receptor with K(i) values of 12.0, 14.0, and 6.7 nM, respectively. The high binding potential of the diastereomeric mixture of aporphine 19 was found residing in the cis-diastereomer (cis-19). [(35)S]GTP gamma S function assays on 5-HT(1A) receptor indicated that aporphines 17 and 20 were partial agonists, while trans-19 behaved as a high efficacy full antagonist and cis-19 was a full agonist. The agonistic property of cis-19 at the 5-HT(1A) receptor was further confirmed in vitro and in vivo. This compound may be useful as a potential treatment for anxiety.",43,ChEMBL,CHEMBL1065707,20180912,10015045|10333842|24766199|46176232|46180191|46180192|46180193|46180194|46180256|46180257|46180258|46180259|46180261|46180325|46180327|46180328|46180331|46180394|46180395|46180396|46180397|46180398|46180399,103201709|103343342|103578872|103725963|103725964|103726032|103726033|103726034|103726035|103726036|103726103|103726104|103726105|103726106|103726107|103726177|103726178|103726179|103726180|103726181|103726182|103726248|103726249,1813,,P14416,Curation Efforts|Research and Development,20041669,0,,P14416,,45.0,,,1,0,1,0,1,0
463386,Literature-derived,Intrinsic activity at human dopamine D2 receptor expressed in CHO cells relative to aripiprazole,"Title: The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure._||_Abstract: The identification of a highly selective D(2) partial agonist, D(3) antagonist tool molecule which demonstrates high levels of brain exposure and selectivity against an extensive range of dopamine, serotonin, adrenergic, histamine, and muscarinic receptors is described.",43,ChEMBL,CHEMBL1106077,20200702,46881408|46881409|46881411|46881412|46881463|46881467|46882004|46882005|46882006|46882009|46882052|46882053|46882054,103741060|103741061|103741063|103741064|103741142|103741146|103742049|103742050|103742051|103742054|103742118|103742119|103742120,1813,,P14416,Curation Efforts|Research and Development,20153647,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
464978,Confirmatory,Inhibition of dopamine D2 receptor,Title: Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity._||_Abstract: Piperazine-bisamide analogs were discovered as partial agonists of human growth hormone secretagogue receptor (GHSR) in a high throughput screen. The partial agonists were optimized for potency and converted into antagonists through structure-activity relationship (SAR) studies. The efforts also led to the identification of potent antagonist with favorable PK profile suitable as a tool compound for in vivo studies.,43,ChEMBL,CHEMBL1101951,20180912,3676358|46880462|46880463|46880498|46880566|46880567|46880568|46880569|46880628|46880629|46880630|46880631|46880672|46880673|46880674,103738709|103738711|103738712|103738777|103738879|103738880|103738881|103738882|103738971|103738972|103738973|103738974|103739038|103739039|103739040,1813,,P14416,Curation Efforts|Research and Development,20137933,0,,P14416,,,,,1,0,1,0,1,0
479242,Confirmatory,Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting,"Title: Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia._||_Abstract: A dihydroquinolinone moiety was found to be a potent serotonin reuptake inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D(2) ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D(2) partial agonists and serotonin reuptake inhibitors. Structure-activity studies revealed that the linker plays a key role in contributing to D(2) affinity, function, and SRI activity.",43,ChEMBL,CHEMBL1110025,20180913,3559|46888925|46888926|46888927|46888928|46888983|46888984|46888985|46888986|46889013|46889014|46889015|46889016|46889041,103167216|103754563|103754564|103754565|103754566|103754670|103754671|103754672|103754673|103754740|103754741|103754742|103754743|103754805,1813,,P14416,Curation Efforts|Research and Development,20347298,0,,P14416,9606.0,,,,1,0,1,0,0,0
516804,Confirmatory,Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells,"Title: 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics._||_Abstract: A series of 6-alkoxyisoindolin-1-ones with a magic shotgun pharmacological profile are presented as potential antipsychotics. The in vitro pharmacological profile includes D(2) partial agonism (30-55%), 5-HT(1A) partial agonism (60-90%), and 5-HT(2A) antagonism. Selected compounds in this series displayed good in vivo activity and potency.",43,ChEMBL,CHEMBL1260558,20180915,60795|24738459|25068794|25068797|25068850|25068903|25068905|25068906|25068907|25068908|25068962|25068963|25068964|25068966|25069015|25069016|25069072|25069073|25069074|25069121|25069122|25069125|25069180|25069181|25069239|25069240|25069241|25069242|25069243|25069297|25069298|25069299|25069300|25069301|25069302|25069353|25069354|25069355|25069356|46946859|52940734|52941358|52941423|52942615|52942854|52942916|52944379|52945060|52945840|52946792|52946835|52947342|52947343|52947380|52948101|52948256|52948620|52949351|52949810|52949885|52950060|52950169,103307946|123083554|123083555|123083807|123084738|123084836|123084920|123084949|123085085|123085186|123085349|123085827|123086308|123087150|123087250|123087351|123087364|123087365|123087379|123087615|123087761|123087770|123088276|123088277|123089296|123089546|123089589|123090100|123090586|123091845|123091878|123092035|123093292|123093925|123093961|123094070|123094145|123094167|123094284|123094672|123095069|123095191|123096195|123096196|123096258|123096299|123096601|123097597|123097866|123097867|123098617|123098711|123098919|123099904|123100854|123100964|123100994|123101103|123101225|123101313|123101314|123101573,1813,,P14416,Curation Efforts|Research and Development,20801650,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
516808,Literature-derived,Intrinsic activity at human dopamine D2L receptor expressed in CHO cells by [3H]-thymidine uptake assay relative to quinpirole,"Title: 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics._||_Abstract: A series of 6-alkoxyisoindolin-1-ones with a magic shotgun pharmacological profile are presented as potential antipsychotics. The in vitro pharmacological profile includes D(2) partial agonism (30-55%), 5-HT(1A) partial agonism (60-90%), and 5-HT(2A) antagonism. Selected compounds in this series displayed good in vivo activity and potency.",43,ChEMBL,CHEMBL1260562,20180915,24738459|25068794|25068797|25068850|25068903|25068905|25068907|25068908|25068962|25068963|25068964|25068966|25069015|25069016|25069072|25069073|25069074|25069121|25069122|25069125|25069180|25069181|46946859|52942854|52942916,123083554|123084738|123085186|123085349|123085827|123087250|123087351|123087364|123087615|123087761|123087770|123088276|123088277|123089296|123089589|123090100|123091845|123092035|123093925|123093961|123094070|123094145|123094672|123096299|123098711,1813,,P14416,Curation Efforts|Research and Development,20801650,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
516809,Literature-derived,Intrinsic activity at human dopamine D2L receptor expressed in CHO cells by FLIPR assay relative to quinpirole,"Title: 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics._||_Abstract: A series of 6-alkoxyisoindolin-1-ones with a magic shotgun pharmacological profile are presented as potential antipsychotics. The in vitro pharmacological profile includes D(2) partial agonism (30-55%), 5-HT(1A) partial agonism (60-90%), and 5-HT(2A) antagonism. Selected compounds in this series displayed good in vivo activity and potency.",43,ChEMBL,CHEMBL1260563,20180915,60795|24738459|25068794|25068797|25068850|25068903|25068905|25068906|25068907|25068908|25068962|25068963|25068964|25068966|25069015|25069016|25069072|25069073|25069074|25069121|25069122|25069125|25069180|25069181|25069239|25069240|25069241|25069242|25069243|25069297|25069298|25069299|25069300|25069301|25069302|25069353|25069354|25069355|25069356|46946859|52940734|52941358|52941423|52942615|52942854|52942916|52944379|52945060|52945840|52946792|52946835|52947342|52947343|52947380|52948101|52948256|52948620|52949351|52949810|52949885|52950060|52950169,103307946|123083554|123083555|123083807|123084738|123084836|123084920|123084949|123085085|123085186|123085349|123085827|123086308|123087150|123087250|123087351|123087364|123087365|123087379|123087615|123087761|123087770|123088276|123088277|123089296|123089546|123089589|123090100|123090586|123091845|123091878|123092035|123093292|123093925|123093961|123094070|123094145|123094167|123094284|123094672|123095069|123095191|123096195|123096196|123096258|123096299|123096601|123097597|123097866|123097867|123098617|123098711|123098919|123099904|123100854|123100964|123100994|123101103|123101225|123101313|123101314|123101573,1813,,P14416,Curation Efforts|Research and Development,20801650,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
594005,Confirmatory,Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells,"Title: Aromatic ring functionalization of benzolactam derivatives: new potent dopamine D3 receptor ligands._||_Abstract: Since the discovery of the dopamine D(3) receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D(3) receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D(1)-D(4) receptors were evaluated and the data led us to highly potent D(3) ligands, some of them highly selective for D(3) receptor, compared to the related dopamine receptor subtypes. Functional D(3) activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity.",43,ChEMBL,CHEMBL1771855,20180918,25256814|25256816|46893146|53327908|54580905|54580906|54581963|54581964|54583897|54583898|54585810|54585811,103631173|103632093|131273733|131273734|131275757|131275758|131279806|131279807|131281795|131283784|131283785|131283786,1813,,P14416,Curation Efforts|Research and Development,21273071,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
594006,Confirmatory,Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells,"Title: Aromatic ring functionalization of benzolactam derivatives: new potent dopamine D3 receptor ligands._||_Abstract: Since the discovery of the dopamine D(3) receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D(3) receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D(1)-D(4) receptors were evaluated and the data led us to highly potent D(3) ligands, some of them highly selective for D(3) receptor, compared to the related dopamine receptor subtypes. Functional D(3) activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity.",43,ChEMBL,CHEMBL1771856,20180918,25256814|25256816|46893146|53327908|54580905|54580906|54581963|54581964|54583897|54583898|54585810|54585811,103631173|103632093|131273733|131273734|131275757|131275758|131279806|131279807|131281795|131283784|131283785|131283786,1813,,P14416,Curation Efforts|Research and Development,21273071,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
595494,Literature-derived,Intrinsic activity at human dopamine D2 receptor expressed in CHO cells by [3H]-thymidine uptake assay relative to quinpirole,"Title: Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder._||_Abstract: The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D(2) partial agonists is described. Our goal was to optimize the affinities for the D(2), 5-HT(2A) and 5-HT(1A) receptors, such that the D(2)/5-HT(2A) ratio was greater than 5 to ensure maximal occupancy of these receptors when the D(2) occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED=0.3mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg).",43,ChEMBL,CHEMBL1776015,20180918,60795|11213062|11495769|11554167|11633739|11647443|11662306|11697676|21073216|21073533|21073563|21073579|21073584|21073587|21073595|21073606|21073656|21073658|21073667|21073690|21073716|21073731|21073788|21073793|21073817|21073872|54586179,103307946|131272680|131272681|131272682|131274635|131274636|131274637|131274638|131274639|131276699|131276700|131278690|131278691|131278692|131278693|131280740|131280741|131282706|131282707|131282708|131282709|131282710|131284707|131284708|131286750|131286751|131286752,1813,,P14416,Curation Efforts|Research and Development,21353774,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
595495,Confirmatory,Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells,"Title: Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder._||_Abstract: The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D(2) partial agonists is described. Our goal was to optimize the affinities for the D(2), 5-HT(2A) and 5-HT(1A) receptors, such that the D(2)/5-HT(2A) ratio was greater than 5 to ensure maximal occupancy of these receptors when the D(2) occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED=0.3mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg).",43,ChEMBL,CHEMBL1776016,20180918,60795|11213062|11495769|11554167|11633739|11647443|11662306|11697676|21073216|21073533|21073563|21073579|21073584|21073587|21073595|21073606|21073656|21073658|21073667|21073690|21073716|21073731|21073788|21073793|21073817|21073872|54586179,103307946|131272680|131272681|131272682|131274635|131274636|131274637|131274638|131274639|131276699|131276700|131278690|131278691|131278692|131278693|131280740|131280741|131282706|131282707|131282708|131282709|131282710|131284707|131284708|131286750|131286751|131286752,1813,,P14416,Curation Efforts|Research and Development,21353774,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
610678,Confirmatory,Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter,"Title: Synthesis and characterization of selective dopamine D receptor ligands using aripiprazole as the lead compound._||_Abstract: A series of compounds structurally related to aripiprazole (1), an atypical antipsychotic and antidepressant used clinically for the treatment of schizophrenia, bipolar disorder, and depression, have been prepared and evaluated for affinity at D(-like) dopamine receptors. These compounds also share structural elements with the classical D(-like) dopamine receptor antagonists, haloperidol, N-methylspiperone, domperidone and benperidol. Two new compounds, 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (6) and 7-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (7) were found to (a) bind to the D receptor subtype with high affinity (K(i) values < 0.3 nM), (b) exhibit >50-fold D versus D receptor binding selectivity and (c) be partial agonists at both the D and D receptor subtype.",43,ChEMBL,CHEMBL1815674,20200629,60795|53248672|53248674|53248676|53249133|56658005|56658007|56661544|56664947|56664949|56664951|56675268|56678598|56678600|56681924|56681926,103307946|134434401|134434402|134438274|134442114|134442115|134442116|134453729|134453730|134457540|134457541|134461348|134461349|134461350|134461351|134461352,1813,,P14416,Curation Efforts|Research and Development,21536445,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
610689,Literature-derived,Intrinsic efficacy at human recombinant D2L receptor expressed in HEK cells assessed as assessed as inhibition of forskolin-induced [3H]cAMP production after 20 mins by spectrophotometry,"Title: Synthesis and characterization of selective dopamine D receptor ligands using aripiprazole as the lead compound._||_Abstract: A series of compounds structurally related to aripiprazole (1), an atypical antipsychotic and antidepressant used clinically for the treatment of schizophrenia, bipolar disorder, and depression, have been prepared and evaluated for affinity at D(-like) dopamine receptors. These compounds also share structural elements with the classical D(-like) dopamine receptor antagonists, haloperidol, N-methylspiperone, domperidone and benperidol. Two new compounds, 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (6) and 7-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (7) were found to (a) bind to the D receptor subtype with high affinity (K(i) values < 0.3 nM), (b) exhibit >50-fold D versus D receptor binding selectivity and (c) be partial agonists at both the D and D receptor subtype.",43,ChEMBL,CHEMBL1815685,20200629,53248672|53249133,134461349|134461350,1813,,P14416,Curation Efforts|Research and Development,21536445,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
622187,Literature-derived,Binding affinity to dopamine D2 receptor at 10 uM by radioligand displacement assay,"Title: Discovery of isoxazole analogues of sazetidine-A as selective 42-nicotinic acetylcholine receptor partial agonists for the treatment of depression._||_Abstract: Depression, a common neurological condition, is one of the leading causes of disability and suicide worldwide. Standard treatment, targeting monoamine transporters selective for the neurotransmitters serotonin and noradrenaline, is not able to help many patients that are poor responders. This study advances the development of sazetidine-A analogues that interact with 42 nicotinic acetylcholine receptors (nAChRs) as partial agonists and that possess favorable antidepressant profiles. The resulting compounds that are highly selective for the 42 subtype of nAChR over 34-nAChRs are partial agonists at the 42 subtype and have excellent antidepressant behavioral profiles as measured by the mouse forced swim test. Preliminary absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies for one promising ligand revealed an excellent plasma protein binding (PPB) profile, low CYP450-related metabolism, and low cardiovascular toxicity, suggesting it is a promising lead as well as a drug candidate to be advanced through the drug discovery pipeline.",43,ChEMBL,CHEMBL1838255,20200629,56595309,134450722,1813,,P14416,Curation Efforts|Research and Development,21905669,0,,P14416,,,,,1,0,1,0,0,0
629461,Confirmatory,Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay,"Title: Development of a bivalent dopamine D receptor agonist._||_Abstract: Bivalent D agonists may function as useful molecular probes for the discovery of novel neurological therapeutics. On the basis of our recently developed bivalent dopamine D receptor antagonists of type 1, the bivalent agonist 2 was synthesized when a spacer built from 22 atoms was employed. Compared to the monovalent control compound 6 containing a capped spacer, the bis-aminoindane derivative 2 revealed substantial steepening of the competition curve, indicating a bivalent binding mode. Dimer-specific Hill slopes were not a result of varying functional properties because both the dopaminergic 2 and the monovalent control agent 6 proved to be D agonists substantially inhibiting cAMP accumulation and inducing D receptor internalization. Investigation of the heterobivalent ligands 8 and 9, containing an agonist and a phenylpiperazine-based antagonist pharmacophore, revealed moderate steepening of the displacement curves and antagonist to very weak partial agonist properties.",43,ChEMBL,CHEMBL1920023,20200626,3559|46917563|46917637|53361301|53361302|56833378|56833379|56833463|56833464,103167216|134444160|134455731|136929125|136929126|136929150|136932376|136942155|136942156,1813,,P14416,Curation Efforts|Research and Development,21999579,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
629462,Confirmatory,Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay,"Title: Development of a bivalent dopamine D receptor agonist._||_Abstract: Bivalent D agonists may function as useful molecular probes for the discovery of novel neurological therapeutics. On the basis of our recently developed bivalent dopamine D receptor antagonists of type 1, the bivalent agonist 2 was synthesized when a spacer built from 22 atoms was employed. Compared to the monovalent control compound 6 containing a capped spacer, the bis-aminoindane derivative 2 revealed substantial steepening of the competition curve, indicating a bivalent binding mode. Dimer-specific Hill slopes were not a result of varying functional properties because both the dopaminergic 2 and the monovalent control agent 6 proved to be D agonists substantially inhibiting cAMP accumulation and inducing D receptor internalization. Investigation of the heterobivalent ligands 8 and 9, containing an agonist and a phenylpiperazine-based antagonist pharmacophore, revealed moderate steepening of the displacement curves and antagonist to very weak partial agonist properties.",43,ChEMBL,CHEMBL1920024,20200626,3559|46917563|46917637|53361301|53361302|56833378|56833379|56833463|56833464,103167216|134444160|134455731|136929125|136929126|136929150|136932376|136942155|136942156,1813,,P14416,Curation Efforts|Research and Development,21999579,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
658857,Literature-derived,Displacement of [3H]N-methylspiperone from D2 at 10 uM,"Title: Chemistry and behavioral studies identify chiral cyclopropanes as selective 42-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile._||_Abstract: Despite their discovery in the early 20th century and intensive study over the last 20 years, nicotinic acetylcholine receptors (nAChRs) are still far from being well understood. Only a few chemical entities targeting nAChRs are currently undergoing clinical trials, and even fewer have reached the marketplace. In our efforts to discover novel and truly selective nAChR ligands, we designed and synthesized a series of chiral cyclopropane-containing 42-specific ligands that display low nanomolar binding affinities and excellent subtype selectivity while acting as partial agonists at 42-nAChRs. Their favorable antidepressant-like properties were demonstrated in the classical mouse forced swim test. Preliminary ADMET studies and broad screening toward other common neurotransmitter receptors were also carried out to further evaluate their safety profile and eliminate their potential off-target activity. These highly potent cyclopropane ligands possess superior subtype selectivity compared to other 42-nAChR agonists reported to date, including the marketed drug varenicline, and therefore may fully satisfy the crucial prerequisite for avoiding adverse side effects. These novel chemical entities could potentially be advanced to the clinic as new drug candidates for treating depression.",43,ChEMBL,CHEMBL2026364,20200626,45254040|56951368|56951495,160678244|160688954|160705128,1813,,P14416,Curation Efforts|Research and Development,22171543,0,,P14416,,,,,1,0,1,0,0,0
697987,Literature-derived,Partial agonist activity at D2 receptor,Title: A straightforward approach for engineering efficacy and selectivity at GPCRs.,43,ChEMBL,CHEMBL2167042,20180923,10454026|10456166,103356575|103402070,1813,,P14416,Curation Efforts|Research and Development,22809299,0,,P14416,,,,,0,1,0,1,0,0
697989,Literature-derived,Partial agonist activity at D2 receptor relative to control,Title: A straightforward approach for engineering efficacy and selectivity at GPCRs.,43,ChEMBL,CHEMBL2167044,20180923,1346|851833|10454026|10456166,103169108|103356575|103402070|163329505,1813,,P14416,Curation Efforts|Research and Development,22809299,0,,P14416,,,,,0,1,0,1,0,0
699930,Literature-derived,Partial agonist activity at human D2S receptor expressed in HEK293T cells coexpressing GalphaoA-91-Rluc8 and mVenus-Gbeta1gamma2 after 2 mins by bioluminescence resonance energy transfer assay relative to dopamine,"Title: Molecular determinants of selectivity and efficacy at the dopamine D3 receptor._||_Abstract: The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders. The high sequence homology between the D3R and D2R, especially within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compounds challenging. Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compounds and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy. We find that selectivity arises from divergent interactions within a second binding pocket (SBP) separate from the OBS, whereas efficacy depends on the binding mode in the OBS. Our findings reveal structural features of the receptor that are critical to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies. These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.",43,ChEMBL,CHEMBL2167814,20180923,851833|10454026|10456166|42626318,103356575|103402070|124969027|163329505,1813,,P14416,Curation Efforts|Research and Development,22632094,0,,P14416,9606.0,54.0,,,0,1,0,1,0,0
714503,Literature-derived,Inhibition of human D2S receptor at 10 uM by CEREP assay,"Title: Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012._||_Abstract: A series of imidazole compounds has been identified which affords potent and selective partial and full agonists of the TAAR1 receptor. Starting from 2-benzyl-imidazoline screening hits, a series of structurally related 2-benzyl- and 4-benzyl-imidazoles was investigated first, but it proved highly challenging to obtain compounds having sufficient selectivity against the adrenergic alpha 2 receptor. This issue could be successfully addressed by modification of the linker region and SAR exploration led to the discovery of highly selective isopropyl-substituted 4-aminomethyl-imidazole compounds. The work culminated in the identification of the selective TAAR1 partial agonist RO5073012 (4-chlorophenyl)-(1H-imidazol-4-ylmethyl)-isopropyl-amine, 24), which has a good pharmacokinetic profile after oral administration in rodents. RO5073012 has been found to be active in a behavioural rat model which is considered indicative for schizophrenia.",43,ChEMBL,CHEMBL2215969,20180924,24781869,163329089,1813,,P14416,Curation Efforts|Research and Development,22795332,0,,P14416,9606.0,,,,1,0,1,0,0,0
718728,Confirmatory,Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis,"Title: Novel azulene derivatives for the treatment of erectile dysfunction._||_Abstract: Based on the dopamine D(4) receptor partial agonist FAUC 3019, a series of azulenylmethylpiperazines was synthesized and affinities for the monoaminergic GPCRs including dopamine, serotonin, histamine and -adrenergic receptor subtypes were determined. Ligand efficacies of the most promising test compounds revealed the N,N-dimethylaminomethyl substituted azulene 11 to be the most potent D(4) partial agonist (EC(50)=0.41 nM). This candidate was investigated for its ability to promote penile erection. Applying an in vivo animal model, test compound 11 turned out to stimulate penile erection in male rats with superior potency in low concentrations when compared to apomorphine.",43,ChEMBL,CHEMBL2214282,20200625,3716121|71450707|71454294|71454295|71456045|71456046|71457844|71459759|71459760|71459761|71461481|71463207,163315507|163322427|163322428|163325826|163325827|163329250|163329251|163332848|163332849|163332850|163336245|163339653,1813,,P14416,Curation Efforts|Research and Development,23099096,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
718729,Confirmatory,Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis,"Title: Novel azulene derivatives for the treatment of erectile dysfunction._||_Abstract: Based on the dopamine D(4) receptor partial agonist FAUC 3019, a series of azulenylmethylpiperazines was synthesized and affinities for the monoaminergic GPCRs including dopamine, serotonin, histamine and -adrenergic receptor subtypes were determined. Ligand efficacies of the most promising test compounds revealed the N,N-dimethylaminomethyl substituted azulene 11 to be the most potent D(4) partial agonist (EC(50)=0.41 nM). This candidate was investigated for its ability to promote penile erection. Applying an in vivo animal model, test compound 11 turned out to stimulate penile erection in male rats with superior potency in low concentrations when compared to apomorphine.",43,ChEMBL,CHEMBL2214283,20200625,3716121|71450707|71454294|71454295|71456045|71456046|71457844|71459759|71459760|71459761|71461481|71463207,163315507|163322427|163322428|163325826|163325827|163329250|163329251|163332848|163332849|163332850|163336245|163339653,1813,,P14416,Curation Efforts|Research and Development,23099096,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
723179,Confirmatory,Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr,"Title: Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HTA/5-HTA/5-HT and dopamine D/D receptors._||_Abstract: A series of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole was synthesized to explore the influence of two structural features - replacement of ether/amide moiety with sulfonamide one, and localization of a sulfonamide group in the azine moiety. In contrast to aripiprazole, compound 33 (N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)quinoline-7-sulfonamide) and 39 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)isoquinoline-3-sulfonamide) displaying multireceptor 5-HT(1A)/5-HT(2A)/5-HT(7)/D(2)/D(3) profile, and behaving as 5-HT(1A) agonists, D(2) partial agonists, and 5-HT(2A)/5-HT(7) antagonists, produced significant antidepressant activity in FST in mice. On the other hand, their 4-isoquinolinyl analog 40 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)isoquinoline-4-sulfonamide), with similar receptor binding and functional profile, additionally displayed remarkable antipsychotic properties in the MK-801-induced hyperlocomotor activity in mice.",43,ChEMBL,CHEMBL2321509,20200626,60795|71574204|71574210|71574212|71574302|71574306,103307946|164127859|164133532|164133572|164144752|164147559,1813,,P14416,Curation Efforts|Research and Development,23279866,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
727075,Confirmatory,Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes,"Title: Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists._||_Abstract: Dopamine (D(2)) partial agonists (D2PAs) have been regarded as a potential treatment for schizophrenia patients with expected better side effect profiles than currently marketed antipsychotics. Herein we report the synthesis and SAR of a series of aminothiazole fused benzazepines as selective D(2) partial agonists. These compounds have good selectivity, CNS drug-like properties and tunable D(2) partial agonism. One of the key compounds, 8h, has good in vitro/in vivo ADME characteristics, and is active in a rat amphetamine-induced locomotor activity model.",43,ChEMBL,CHEMBL2328745,20180925,60795|119570|208951|44182375|71500036|71540967|71541076|71541077|71541078|71541079|71541080|71541081|71541082|71541083|71541084|71541174|71541175|71541176|71541177|71541178|71541179|71541180|71541275|71541276|71541277|71541278|71541279|71541280,103245538|103307946|103506288|164128964|164128965|164128966|164128967|164128968|164131811|164131812|164131813|164134659|164134660|164134661|164140299|164140300|164140301|164140302|164140303|164143061|164143062|164143063|164143064|164143065|164145834|164148671|164148672|164148673,1813,,P14416,Curation Efforts|Research and Development,23237836,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
729713,Confirmatory,Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter,"Title: Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile._||_Abstract: An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D(1), D(2) and serotonin 5-HT(1A) and 5-HT(2A) receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D(1) receptor with K(i) values of 50 and 6.3nM, while both compounds act as D(2) receptor antagonists (K(i)=305 and 145nM, respectively) and 5-HT(1A) receptor full agonists (K(i)=149 and 908nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT(1A) receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.",43,ChEMBL,CHEMBL2343279,20180926,5018|5202|5265|21171|72301|161665|188442|439654|440229|443422|969488|1152279|3246443|6917970|11155278|11186895|11282465|12304090|12313091|12442999|14378574|36791366|70690499|70690500|70692655|70692656|71109804|71109805|71109897|71261649|71524563|71524612|71524613|71524658,103165719|103167959|103313125|103579214|103579226|103597736|103617112|103638093|103654473|104234153|104252109|160690592|160690593|160696009|160696010|164127582|164132292|164132293|164132294|164135115|164135116|164135117|164135118|164135119|164136603|164136604|164138002|164140783|164141679|164143550|164143551|164146281|164146282|164149173,1813,,P14416,Curation Efforts|Research and Development,23332346,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
729717,Literature-derived,Inhibition of [3H]spiperone binding to dopamine D2 receptor (unknown origin) expressed in human HEK293 cells at 10 uM by liquid scintillation counter relative to control,"Title: Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile._||_Abstract: An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D(1), D(2) and serotonin 5-HT(1A) and 5-HT(2A) receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D(1) receptor with K(i) values of 50 and 6.3nM, while both compounds act as D(2) receptor antagonists (K(i)=305 and 145nM, respectively) and 5-HT(1A) receptor full agonists (K(i)=149 and 908nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT(1A) receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.",43,ChEMBL,CHEMBL2343283,20180926,5018|5202|5265|21171|72301|161665|188442|439654|440229|443422|969488|1152279|3246443|6917970|11155278|11186895|11282465|12304090|12313091|12442999|14378574|36791366|70690499|70690500|70692655|70692656|71109804|71109805|71109897|71261649|71524563|71524612|71524613|71524658,103165719|103167959|103313125|103579214|103579226|103597736|103617112|103638093|103654473|104234153|104252109|160690592|160690593|160696009|160696010|164127582|164132292|164132293|164132294|164135115|164135116|164135117|164135118|164135119|164136603|164136604|164138002|164140783|164141679|164143550|164143551|164146281|164146282|164149173,1813,,P14416,Curation Efforts|Research and Development,23332346,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
733804,Confirmatory,Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells,"Title: Discovery of dopamine D receptor antagonists with planar chirality._||_Abstract: Employing the D4 selective phenylpiperazine 2 as a lead compound, planar chiral analogs with paracyclophane substructure were synthesized and evaluated for their ability to bind and activate dopamine receptors. The study revealed that the introduction of a [2.2]paracyclophane moiety is tolerated by dopamine receptors of the D2 family. Subtype selectivity for D4 and ligand efficacy depend on the absolute configuration of the test compounds. Whereas the achiral single-layered lead 2 and the double-layered paracyclophane (R)-3 showed partial agonist properties, the enantiomer (S)-3 behaved as a neutral antagonist.",43,ChEMBL,CHEMBL2346426,20200626,681|10403608|71583848|71583849,103167911|103490530|164132547|164146529,1813,,P14416,Curation Efforts|Research and Development,23428965,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
733806,Confirmatory,Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells,"Title: Discovery of dopamine D receptor antagonists with planar chirality._||_Abstract: Employing the D4 selective phenylpiperazine 2 as a lead compound, planar chiral analogs with paracyclophane substructure were synthesized and evaluated for their ability to bind and activate dopamine receptors. The study revealed that the introduction of a [2.2]paracyclophane moiety is tolerated by dopamine receptors of the D2 family. Subtype selectivity for D4 and ligand efficacy depend on the absolute configuration of the test compounds. Whereas the achiral single-layered lead 2 and the double-layered paracyclophane (R)-3 showed partial agonist properties, the enantiomer (S)-3 behaved as a neutral antagonist.",43,ChEMBL,CHEMBL2346428,20200626,681|10403608|71583848|71583849,103167911|103490530|164132547|164146529,1813,,P14416,Curation Efforts|Research and Development,23428965,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
764181,Confirmatory,Binding affinity to dopamine 2 receptor (unknown origin),"Title: Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates._||_Abstract: The 5-HT1AR partial agonist PET radiotracer, [(11)C]CUMI-101, has advantages over an antagonist radiotracer as it binds preferentially to the high affinity state of the receptor and thereby provides more functionally meaningful information. The major drawback of C-11 tracers is the lack of cyclotron facility in many health care centers thereby limiting widespread clinical or research use. We identified the fluoroethyl derivative, 2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione (FECUMI-101) (Ki=0.1nM; Emax=77%; EC50=0.65nM) as a partial agonist 5-HT1AR ligand of the parent ligand CUMI-101. FECUMI-101 is radiolabeled with F-18 by O-fluoroethylation of the corresponding desmethyl analogue (1) with [(18)F]fluoroethyltosylate in DMSO in the presence of 1.6equiv of K2CO3 in 455% yield (EOS). PET shows [(18)F]FECUMI-101 binds specifically to 5-HT1AR enriched brain regions of baboon. The specificity of [(18)F]FECUMI-101 binding to 5-HT1AR was confirmed by challenge studies with the known 5-HT1AR ligand WAY100635. These findings indicate that [(18)F]FECUMI-101 can be a viable agonist ligand for the in vivo quantification of high affinity 5-HT1AR with PET.",43,ChEMBL,CHEMBL2416736,20200629,21830793|73346042,174487458|174487459,1813,,P14416,Curation Efforts|Research and Development,23816046,0,,P14416,9606.0,,,,1,0,1,0,1,0
780771,Confirmatory,Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells,"Title: Click chemistry based synthesis of dopamine D4 selective receptor ligands for the selection of potential PET tracers._||_Abstract: Taking advantage of click chemistry, a library of N-arylpiperazinylmethyl triazoles bearing fluoro substituted appendages was synthesized and the target compounds were investigated for dopamine and serotonin receptor binding. With the aim to bias their hydrophilicity and to optimize their D4 receptor affinity and selectivity, a concise series of triazoles containing fluoroalkyl, fluoroalkoxy, fluoroalkoxyphenyl, and deoxyfluoroglucosyl substituents was studied. The D4 receptor affinity and selectivity could be tuned by altering the chemical moiety attached to the triazole unit. Among the test compounds, the fluoroethoxyphenyl derivative 15b showed weak partial agonism at D4 and a K(i) value of 14 nM, while its fluoropropoxyphenyl homologue 16a turned out to act as a neutral D4 antagonist (K(i)=5.1 nM). Both, 15b and 16a revealed an excellent balance between D4 receptor affinity and subtype selectivity, providing lead candidates for the development of (18)F-labeled radioligands for D4 receptor imaging studies by positron emission tomography (PET).",43,ChEMBL,CHEMBL2443402,20180928,44412269|72544566|72544787|72544789|72545007|72545008|72545009|72545010|72545011|72545238|72545239|72545240,103489982|174489343|174489344|174494364|174494365|174499533|174499534|174504767|174504768|174515048|174515049|174515050,1813,,P14416,Curation Efforts|Research and Development,24100078,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
780772,Confirmatory,Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells,"Title: Click chemistry based synthesis of dopamine D4 selective receptor ligands for the selection of potential PET tracers._||_Abstract: Taking advantage of click chemistry, a library of N-arylpiperazinylmethyl triazoles bearing fluoro substituted appendages was synthesized and the target compounds were investigated for dopamine and serotonin receptor binding. With the aim to bias their hydrophilicity and to optimize their D4 receptor affinity and selectivity, a concise series of triazoles containing fluoroalkyl, fluoroalkoxy, fluoroalkoxyphenyl, and deoxyfluoroglucosyl substituents was studied. The D4 receptor affinity and selectivity could be tuned by altering the chemical moiety attached to the triazole unit. Among the test compounds, the fluoroethoxyphenyl derivative 15b showed weak partial agonism at D4 and a K(i) value of 14 nM, while its fluoropropoxyphenyl homologue 16a turned out to act as a neutral D4 antagonist (K(i)=5.1 nM). Both, 15b and 16a revealed an excellent balance between D4 receptor affinity and subtype selectivity, providing lead candidates for the development of (18)F-labeled radioligands for D4 receptor imaging studies by positron emission tomography (PET).",43,ChEMBL,CHEMBL2443403,20180928,44412269|72544566|72544787|72544789|72545007|72545008|72545009|72545010|72545011|72545238|72545239|72545240,103489982|174489343|174489344|174494364|174494365|174499533|174499534|174504767|174504768|174515048|174515049|174515050,1813,,P14416,Curation Efforts|Research and Development,24100078,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1054306,Confirmatory,Displacement of [3H]-NPA from dopamine D2L receptor (unknown origin) expressed in CHO cell membranes,"Title: A structure-activity analysis of biased agonism at the dopamine D2 receptor._||_Abstract: Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.",43,ChEMBL,CHEMBL3089791,20180928,681,103167911,1813,,P14416,Curation Efforts|Research and Development,24138311,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
1054309,Confirmatory,Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis,"Title: A structure-activity analysis of biased agonism at the dopamine D2 receptor._||_Abstract: Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.",43,ChEMBL,CHEMBL3089794,20180928,10596144|11154555|46929184|68630558|72735990|72735991|72736197|72736198|72736199|72736200|72736201|72736202|72736203|72736378|72736379|72736380|72736381|72736382|72736383|72736555,160694505|194137961|194137962|194137963|194137964|194144851|194145147|194145148|194145149|194151677|194151678|194151679|194151680|194151988|194158685|194158961|194158962|194165628|194165629|194165630|194172492|194186174|194186449|194186450,1813,,P14416,Curation Efforts|Research and Development,24138311,0,,P14416,9606.0,197.0,,,1,0,1,0,0,0
1077534,Confirmatory,Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay,"Title: Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands._||_Abstract: A series of substituted 1H-indolyl carboxylic acid amides that contain a N-(2-methoxyphenyl)piperazine or N-(2-fluoroethoxy)piperazine group were synthesized and their affinities for human dopamine D2, D3, and D4 receptors were determined. Two of these compounds, 14a and 14b, displayed high binding affinity at D3 (Ki = 0.18 and 0.4 nM, respectively), and selectivity for D3vs. D2 receptors (87-fold and 60-fold, respectively). These two compounds had low binding affinity at D4 receptors and  receptor sites. The intrinsic activity of these compounds at D2 and D3 receptors was determined using a forskolin-dependent adenylyl cyclase inhibition assay; both 14a and 14b were found to be partial agonists. Furthermore, for compound 14a, the log D value of 2.85 suggested it has suitable lipophilicity for crossing the blood-brain-barrier.",43,ChEMBL,CHEMBL3136930,20200620,76311261|76311270|76311272|76314861|76318472|76318474|76318476|76322139|76322141|76325763|76329346|76332978|76332985|76332987|76332989|76336596,194140841|194140851|194140852|194147665|194154589|194154590|194154591|194161526|194161527|194168458|194175286|194182111|194182118|194182119|194182120|194188964,1813,,P14416,Curation Efforts|Research and Development,24156012,0,,P14416,9606.0,45.0,,,1,0,1,0,0,0
1153295,Confirmatory,Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay,"Title: Functionally selective dopamine D, D receptor partial agonists._||_Abstract: Dopamine D2 receptor-promoted activation of G(o) over G(i) may increase synaptic plasticity and thereby might improve negative symptoms of schizophrenia. Heterocyclic dopamine surrogates comprising a pyrazolo[1,5-a]pyridine moiety were synthesized and investigated for their binding properties when low- to subnanomolar K(i) values were determined for D(2L), D(2S), and D3 receptors. Measurement of [(35)S]GTPS incorporation at D(2S) coexpressed with G-protein subunits indicated significant bias for promotion of G(o1) over G(i2) coupling for several test compounds. Functionally selective D(2S) activation was most striking for the carbaldoxime 8b (G(o1), pEC50 = 8.87, E(max) = 65%; G(i2), pEC50 = 6.63, E(max) = 27%). In contrast, the investigated 1,4-disubstituted aromatic piperazines (1,4-DAPs) behaved as antagonists for -arrestin-2 recruitment, implying significant ligand bias for G-protein activation over -arrestin-2 recruitment at D(2S) receptors. Ligand efficacy and selectivity between D(2S) and D3 activation were strongly influenced by regiochemistry and the nature of functional groups attached to the pyrazolo[1,5-a]pyridine moiety.",43,ChEMBL,CHEMBL3295080,20200618,54562|60795|11154555|25070416|25070419|25070740|25070742|25071066|25071384|25071691|25071692|25072632|25072635|25072943|25072946|90644226|90644227|90644228|90644230|136056636,103307946|103543557|160694505|242646172|242646173|242646174|242646175|242646176|242646177|242646178|242646179|242646180|242646181|242646182|242646183|242646184|242646185|242646186|242646187|242646188,1813,,P14416,Curation Efforts|Research and Development,24831693,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1153296,Confirmatory,Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay,"Title: Functionally selective dopamine D, D receptor partial agonists._||_Abstract: Dopamine D2 receptor-promoted activation of G(o) over G(i) may increase synaptic plasticity and thereby might improve negative symptoms of schizophrenia. Heterocyclic dopamine surrogates comprising a pyrazolo[1,5-a]pyridine moiety were synthesized and investigated for their binding properties when low- to subnanomolar K(i) values were determined for D(2L), D(2S), and D3 receptors. Measurement of [(35)S]GTPS incorporation at D(2S) coexpressed with G-protein subunits indicated significant bias for promotion of G(o1) over G(i2) coupling for several test compounds. Functionally selective D(2S) activation was most striking for the carbaldoxime 8b (G(o1), pEC50 = 8.87, E(max) = 65%; G(i2), pEC50 = 6.63, E(max) = 27%). In contrast, the investigated 1,4-disubstituted aromatic piperazines (1,4-DAPs) behaved as antagonists for -arrestin-2 recruitment, implying significant ligand bias for G-protein activation over -arrestin-2 recruitment at D(2S) receptors. Ligand efficacy and selectivity between D(2S) and D3 activation were strongly influenced by regiochemistry and the nature of functional groups attached to the pyrazolo[1,5-a]pyridine moiety.",43,ChEMBL,CHEMBL3295081,20200618,54562|60795|11154555|25070416|25070419|25070740|25070742|25071066|25071384|25071691|25071692|25072632|25072635|25072943|25072946|90644226|90644227|90644228|90644230|136056636,103307946|103543557|160694505|242646172|242646173|242646174|242646175|242646176|242646177|242646178|242646179|242646180|242646181|242646182|242646183|242646184|242646185|242646186|242646187|242646188,1813,,P14416,Curation Efforts|Research and Development,24831693,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1154609,Confirmatory,Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294601,20200618,53304086|53327181|53327217|53327218|53327219|53327220|53327221|53327222|53327260|53327261|53327262|53327263|67325096,242645340|242645341|242645342|242645343|242645344|242645345|242645346|242645347|242645348|242645349|242645350|242645351|242645352,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,,,,1,0,1,0,1,0
1154610,Confirmatory,Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294602,20200618,28864|31101|47811,103170197|103175300|103408740,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1154611,Confirmatory,Displacement of [3H]nemonapride from dopamine D2L receptor (unknown origin) expressed in African green monkey COS7 cells,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294603,20200618,208951,103506288,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,207.0,,,1,0,1,0,1,0
1154612,Literature-derived,Intrinsic activity at human dopamine D2L receptor expressed in CHOK1a cell membrane assessed as [125I]-cAMP accumulation after 20 mins,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294604,20200618,53304086|53327181|53327217|53327218|53327219|53327220|53327221|53327222|53327260|53327261|53327262|53327263|67325096,242645340|242645341|242645342|242645343|242645344|242645345|242645346|242645347|242645348|242645349|242645350|242645351|242645352,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,,,,1,0,1,0,1,0
1154613,Literature-derived,Intrinsic activity at human dopamine D2L receptor expressed in CHO cells by [35S]GTPgammaS binding assay,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294605,20200618,28864|31101|47811,103170197|103175300|103408740,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1154614,Literature-derived,Intrinsic activity at human dopamine D2L receptor expressed in Sf9 cell membrane by [35S]GTPgammaS binding assay,"Title: Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT and dopamine D receptor ligands._||_Abstract: By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively. While the 5-HT6 ligands were antagonists, the D2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.",43,ChEMBL,CHEMBL3294606,20200618,208951,103506288,1813,,P14416,Curation Efforts|Research and Development,24878269,0,,P14416,9606.0,521.0,,,1,0,1,0,1,0
1169860,Confirmatory,Binding affinity to dopamine D2 receptor (unknown origin),"Title: Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies._||_Abstract: Combination of dopamine D3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structure-activity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.",43,ChEMBL,CHEMBL3381713,20181005,5073|60795|11350623|11494093|11501253|11501537|11537385|11567578|11567928|11603119|11603486|11625642|11638640|11639248|11676638|11696813|24769156|34257212|51122451|57456630|57873490|57873491|57873492|57873499|57873504|57873508|57873513|57873515|57873518|57873520|57873522|57873525|57873527|57873531|60204111|60204112|118722639|118722912|118722913|118722914|118722915|135398737|135398745,103165765|103170825|103195217|103307946|103627886|312371860|312371861|312371862|312371863|312371864|312371865|312371866|312371867|312371868|312371869|312372258|312372259|312372260|312372261|312372262|312372263|312372264|312372265|312372266|312372267|312372268|312372269|312372270|312372271|312372272|312372273|312372274|312372275|312372276|312372277|312372278|312372279|312372280|312372281|312372282|312372283|312372284|312372285,1813,,P14416,Curation Efforts|Research and Development,25343529,0,,P14416,9606.0,,,,1,0,1,0,1,0
1187722,Confirmatory,Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method,"Title: Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity._||_Abstract: Antagonist and partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders. However, development of druglike lead compounds with selectivity for the D3 receptor has been challenging because of the high sequence homology between the D3R and the dopamine D2 receptor (D2R). In this effort, we synthesized a series of acylaminobutylpiperazines incorporating aza-aromatic units and evaluated their binding and functional activities at the D3 and D2 receptors. Docking studies and results from evaluations against a set of chimeric and mutant receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.",43,ChEMBL,CHEMBL3379351,20181006,11675867|66574145|73670899|73671061|73671062|73671216|73671217|73671218|73671219|73671367|117869686|117870140|117870408|117870413|117870490|117870714|117870915|117870976|117871054|117871069|117871083|118710458|118710459|118710460|118710461|118710462|118710463|118710464|118710465|118710466|118710467|118710468|118710469|118710470,312352922|312352923|312352924|312352925|312352926|312352927|312352928|312352929|312352930|312352931|312352932|312352933|312352934|312352935|312352936|312352937|312352938|312352939|312352940|312352941|312352942|312352943|312352944|312352945|312352946|312352947|312352948|312352949|312353043|312353044|312353045|312353046|312353047|312353048,1813,,P14416,Curation Efforts|Research and Development,25126833,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1187725,Confirmatory,Displacement of [125I]IABN from wild type human D2R expressed in HEK293 cell membranes by gamma counting method,"Title: Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity._||_Abstract: Antagonist and partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders. However, development of druglike lead compounds with selectivity for the D3 receptor has been challenging because of the high sequence homology between the D3R and the dopamine D2 receptor (D2R). In this effort, we synthesized a series of acylaminobutylpiperazines incorporating aza-aromatic units and evaluated their binding and functional activities at the D3 and D2 receptors. Docking studies and results from evaluations against a set of chimeric and mutant receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.",43,ChEMBL,CHEMBL3379354,20181006,66574145|117870140|117871069,312352941|312353043|312353045,1813,,P14416,Curation Efforts|Research and Development,25126833,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1187727,Confirmatory,Displacement of [125I]IABN from chimeric human D2 receptor possessing extracellular loop II of D3 receptor expressed in HEK293 cell membranes by gamma counting method,"Title: Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity._||_Abstract: Antagonist and partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders. However, development of druglike lead compounds with selectivity for the D3 receptor has been challenging because of the high sequence homology between the D3R and the dopamine D2 receptor (D2R). In this effort, we synthesized a series of acylaminobutylpiperazines incorporating aza-aromatic units and evaluated their binding and functional activities at the D3 and D2 receptors. Docking studies and results from evaluations against a set of chimeric and mutant receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.",43,ChEMBL,CHEMBL3379897,20181006,66574145|117870140|117871069,312352941|312353043|312353045,1813,,P14416,Curation Efforts|Research and Development,25126833,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1196314,Confirmatory,Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method,"Title: Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia._||_Abstract: We describe a novel class of designed multiple ligands (DMLs) combining serotonin 5-HT6 receptor (5-HT6R) antagonism with dopamine D2 receptor (D2R) partial agonism. Prototype hybrid molecules were designed using docking to receptor homology models. Diverse pharmacophore moieties yielded 3 series of hybrids with varying in vitro properties at 5-HT6R and D2R, and at M1 receptor and hERG channel antitargets. 4-(piperazin-1-yl)-1H-indole derivatives showed highest antagonist potency at 5-HT6R, with 7-butoxy-3,4-dihydroquinolin-2(1H)-one and 2-propoxybenzamide derivatives having promising D2R partial agonism. 2-(3-(4-(1-(phenylsulfonyl)-1H-indol-4-yl)piperazin-1-yl)propoxy)benzamide (47) exhibited nanomolar affinity at both 5-HT6R and D2R and was evaluated in rat models. It displayed potent antidepressant-like and anxiolytic-like activity in the Porsolt and Vogel tests, respectively, more pronounced than that of a reference selective 5-HT6R antagonist or D2R partial agonist. In addition, 47 also showed antidepressant-like activity (Porsolt's test) and anxiolytic-like activity (open field test) in aged (>18-month old) rats. In operant conditioning tests, 47 enhanced responding for sweet reward in the saccharin self-administration test, consistent with anti-anhedonic properties. Further, 47 facilitated extinction of non-reinforced responding for sweet reward, suggesting potential procognitive activity. Taken together, these studies suggest that DMLs combining 5-HT6R antagonism and D2R partial agonism may successfully target affective disorders in patients from different age groups without a risk of cognitive deficits.",43,ChEMBL,CHEMBL3413541,20181006,3559|71151588|71151591|71151664|71151683|71151704|71151756|71151757|71151767|71151870|71151889|71151924|71151925|71151929|71151933|71151953|71152026|71502591|71502631|71502632|71502633|71502676|118731502|118731503|118731504|118731505|118731506|118731507|118731508|118731509|118731510|118731511|118731512|118731513,103167216|312385560|312385561|312385562|312385563|312385564|312385565|312385566|312385567|312385568|312385569|312385570|312385571|312385572|312385573|312385574|312385575|312385576|312385577|312385578|312385579|312385580|312385581|312385582|312385583|312385584|312385585|312385586|312385587|312385588|312385589|312385590|312385591|312385592,1813,,P14416,Curation Efforts|Research and Development,25557493,0,,P14416,9606.0,198.0,,,1,0,1,0,1,0
1196326,Confirmatory,Displacement of [3H]methylspiperone from human D2S receptor expressed in HEK293 cells,"Title: Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia._||_Abstract: We describe a novel class of designed multiple ligands (DMLs) combining serotonin 5-HT6 receptor (5-HT6R) antagonism with dopamine D2 receptor (D2R) partial agonism. Prototype hybrid molecules were designed using docking to receptor homology models. Diverse pharmacophore moieties yielded 3 series of hybrids with varying in vitro properties at 5-HT6R and D2R, and at M1 receptor and hERG channel antitargets. 4-(piperazin-1-yl)-1H-indole derivatives showed highest antagonist potency at 5-HT6R, with 7-butoxy-3,4-dihydroquinolin-2(1H)-one and 2-propoxybenzamide derivatives having promising D2R partial agonism. 2-(3-(4-(1-(phenylsulfonyl)-1H-indol-4-yl)piperazin-1-yl)propoxy)benzamide (47) exhibited nanomolar affinity at both 5-HT6R and D2R and was evaluated in rat models. It displayed potent antidepressant-like and anxiolytic-like activity in the Porsolt and Vogel tests, respectively, more pronounced than that of a reference selective 5-HT6R antagonist or D2R partial agonist. In addition, 47 also showed antidepressant-like activity (Porsolt's test) and anxiolytic-like activity (open field test) in aged (>18-month old) rats. In operant conditioning tests, 47 enhanced responding for sweet reward in the saccharin self-administration test, consistent with anti-anhedonic properties. Further, 47 facilitated extinction of non-reinforced responding for sweet reward, suggesting potential procognitive activity. Taken together, these studies suggest that DMLs combining 5-HT6R antagonism and D2R partial agonism may successfully target affective disorders in patients from different age groups without a risk of cognitive deficits.",43,ChEMBL,CHEMBL3413553,20181006,37459|71151588,103167599|312385585,1813,,P14416,Curation Efforts|Research and Development,25557493,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1232271,Confirmatory,Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis,"Title: Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands._||_Abstract: The dopamine D3 receptor (D3R) is a target of pharmacotherapeutic interest in a variety of neurological disorders including schizophrenia, Parkinson's disease, restless leg syndrome, and drug addiction. A common molecular template used in the development of D3R-selective antagonists and partial agonists incorporates a butylamide linker between two pharmacophores, a phenylpiperazine moiety and an extended aryl ring system. The series of compounds described herein incorporates a change to that chemical template, replacing the amide functional group in the linker chain with a 1,2,3-triazole group. Although the amide linker in the 4-phenylpiperazine class of D3R ligands has been previously deemed critical for high D3R affinity and selectivity, the 1,2,3-triazole moiety serves as a suitable bioisosteric replacement and maintains desired D3R-binding functionality of the compounds. Additionally, using mouse liver microsomes to evaluate CYP450-mediated phase I metabolism, we determined that novel 1,2,3-triazole-containing compounds modestly improves metabolic stability compared to amide-containing analogues. The 1,2,3-triazole moiety allows for the modular attachment of chemical subunit libraries using copper-catalyzed azide-alkyne cycloaddition click chemistry, increasing the range of chemical entities that can be designed, synthesized, and developed toward D3R-selective therapeutic agents.",43,ChEMBL,CHEMBL3591124,20181008,25141534|72190766|118719792|122180568|122180569|122180570|122180571|122180572|122180573|122180574|122180575|122180576|122180610|122180611|122180612|122180613|122180614|122180615|122180616|122180617|122180618|122180619|122180620|122180621|122180622|122180623|122180624|122180625|122180626|122180627|122181005|122181006|122181007,124966353|174493497|312367617|318375884|318375885|318375886|318375887|318375888|318375889|318375890|318375891|318375892|318375953|318375954|318375955|318375956|318375957|318375958|318375959|318375960|318375961|318375962|318375963|318375964|318375965|318375966|318375967|318375968|318375969|318375970|318376629|318376630|318376631,1813,,P14416,Curation Efforts|Research and Development,25650314,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1232327,Confirmatory,Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells,"Title: Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis._||_Abstract: The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders. D3R-selective compounds with high affinity and varying efficacies have been discovered, providing critical research tools for cell-based studies that have been translated to in vivo models of drug abuse. D3R antagonists and partial agonists have shown especially promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking. However, to date, translation to human studies has been limited. Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compounds toward clinical utility, especially for treatment of cocaine abuse. Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to determine the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.",43,ChEMBL,CHEMBL3591366,20181008,60795|9891901|11477180|11784937|42626172|122181334,103252237|103307946|103440257|124958487|318377068|318377069,1813,,P14416,Curation Efforts|Research and Development,25826710,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1232333,Confirmatory,Binding affinity to human dopamine D2 receptor,"Title: Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis._||_Abstract: The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders. D3R-selective compounds with high affinity and varying efficacies have been discovered, providing critical research tools for cell-based studies that have been translated to in vivo models of drug abuse. D3R antagonists and partial agonists have shown especially promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking. However, to date, translation to human studies has been limited. Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compounds toward clinical utility, especially for treatment of cocaine abuse. Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to determine the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.",43,ChEMBL,CHEMBL3591527,20181008,122181334,318377069,1813,,P14416,Curation Efforts|Research and Development,25826710,0,,P14416,9606.0,,,,1,0,1,0,1,0
1232972,Literature-derived,Displacement of [3H]methylspiperione from human D2 receptor expressed in CHO cells at 1 uM by scintillation counting analysis,"Title: Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent._||_Abstract: A series of novel spirohydantoin derivatives with arylpiperazinylbutyl moiety were synthesized and evaluated for serotonin 5-HT1A, 5-HT2A, 5-HT7 and dopamine D2 receptors. Based on these data, four compounds were selected for further binding affinity assays on dopamine D1, D3, D4, and 5-HT2C, 5-HT6 as well as adrenergic 1 and 2C receptors, which are involved in various CNS diseases such as schizophrenia, anxiety and/or depression. The compound 14, 1-{4-[4-(2-metoxyphe-nyl)piperazin-1-yl]butyl}-3',4'-dihydro-2H,2'H,5H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione, with the most promising functional profile, mixed 5-HT2A/D2 antagonist and 5-HT1A partial agonist, was selected. In the mouse d-amphetamine-induced locomotor hyperactivity model, compound 14 produced antipsychotic-like activity, which is devoid of cataleptogenic effects and in the forced swim test in mice, it showed a significant antidepressant-like effect unlike the reference drug aripiprazole.",43,ChEMBL,CHEMBL3592645,20200624,122181251|122181252|122181337|122181338,318376959|318376960|318377072|318377073,1813,,P14416,Curation Efforts|Research and Development,25936259,0,,P14416,9606.0,197.0,,,1,0,1,0,1,0
1255853,Literature-derived,Binding affinity to dopamine D2 receptor (unknown origin) at 3 uM by radioligand-binding assay,"Title: Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists._||_Abstract: We designed and synthesized a series of dihydroquinazolinone derivatives as selective M1 and M4 muscarinic acetylcholine receptors agonists. Introduction of the N-carbethoxy piperidine unit into a HTS hit compound followed by optimization of the amine linker and the carbamoyl moiety led to the identification of compound 1 as a potential candidate. The identified compound 1 showed high selectivity for M1 and M4 muscarinic acetylcholine receptors with M4 partial agonistic activity. In addition, compound 1 showed good brain penetration and reversed methamphetamine-induced hyperlocomotion in rats (ED50=3.0 mg/kg, sc).",43,ChEMBL,CHEMBL3635150,20181009,122195090,318396259,1813,,P14416,Curation Efforts|Research and Development,26428869,0,,P14416,9606.0,,,,1,0,1,0,0,0
1265364,Literature-derived,Ratio of Ki for human D2 receptor to EC50 for human D2 receptor,"Title: Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease._||_Abstract: Our structure-activity relationship studies with N(6)-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives led to development of a lead compound (-)-21a which exhibited very high affinity (Ki, D2 = 16.4 nM, D3 = 1.15 nM) and full agonist activity (EC50 (GTPS); D2 = 3.23 and D3 = 1.41 nM) at both D2 and D3 receptors. A partial agonist molecule (-)-34 (EC50 (GTPS); D2 = 21.6 (Emax = 27%) and D3 = 10.9 nM) was also identified. In a Parkinson's disease (PD) animal model, (-)-21a was highly efficacious in reversing hypolocomotion in reserpinized rats with a long duration of action, indicating its potential as an anti-PD drug. Compound (-)-34 was also able to elevate locomotor activity in the above PD animal model significantly, implying its potential application in PD therapy. Furthermore, (-)-21a was shown to be neuroprotective in protecting neuronal PC12 from toxicity of 6-OHDA. This report, therefore, underpins the notion that a multifunctional drug like (-)-21a might have the potential not only to ameliorate motor dysfunction in PD patients but also to modify disease progression by protecting DA neurons from progressive degeneration.",43,ChEMBL,CHEMBL3745231,20200623,681,103167911,1813,,P14416,Curation Efforts|Research and Development,26555041,0,,P14416,9606.0,,,,1,0,1,0,0,0
1301296,Literature-derived,Partial agonist activity at human dopamine D2 receptor assessed as intrinsic activity,"Title: Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics._||_Abstract: In the present study, a series of benzamides, endowed with potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties, was synthesized and evaluated as potential antipsychotics. Among them, 3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-N-methylbenzamide (21) and its fluoro-substituted analogue (22) held the best pharmacological binding profiles. They not only presented potent activities for D2, 5-HT1A, and 5-HT2A receptors, but were also endowed with low activities for 5-HT2C, H1 receptors and hERG channels, suggesting a low propensity of inducing weight gain and QT prolongation. In animal models, compounds 21 and 22 reduced phencyclidine-induced hyperactivity with a high threshold for catalepsy induction. It thus provides potential candidates for further preclinical studies.",43,ChEMBL,CHEMBL3806885,20180906,60795,103307946,1813,,P14416,Curation Efforts|Research and Development,27173799,0,,P14416,9606.0,,,,0,1,0,1,0,0
1442556,Confirmatory,Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis,"Title: Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure._||_Abstract: 1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors. Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties. In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists. Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over -arrestin recruitment at dopamine D2 receptors. The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo. Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.",43,ChEMBL,CHEMBL4010153,20200620,60795|24936042|25071385|25072002|25072633|25072941|25093832|137633705|137633863|137636351|137636460|137638973|137640203|137640371|137640391|137642380|137643309|137643951|137644833|137644966|137651073|137651936|137655451|137655735|137657115|137657153|137659303|137659990|137660837,103307946|381837327|381839991|381840253|381841350|381841895|381843977|381844146|381847923|381849711|381849986|381850019|381852964|381854346|381855275|381856566|381856760|381857879|381865787|381867052|381872309|381872727|381878882|381879071|381883347|381883441|381884437|381885712|381886168,1813,,P14416,Curation Efforts|Research and Development,28248104,0,,P14416,9606.0,,,,1,0,1,0,0,0
1442559,Confirmatory,Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis,"Title: Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure._||_Abstract: 1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors. Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties. In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists. Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over -arrestin recruitment at dopamine D2 receptors. The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo. Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.",43,ChEMBL,CHEMBL4010156,20200620,60795|24936042|25071385|25072002|25072633|25072941|25093832|137633705|137633863|137636351|137636460|137638973|137640203|137640371|137640391|137642380|137643309|137643951|137644833|137644966|137651073|137651936|137655451|137655735|137657115|137657153|137659303|137659990|137660837,103307946|381837327|381839991|381840253|381841350|381841895|381843977|381844146|381847923|381849711|381849986|381850019|381852964|381854346|381855275|381856566|381856760|381857879|381865787|381867052|381872309|381872727|381878882|381879071|381883347|381883441|381884437|381885712|381886168,1813,,P14416,Curation Efforts|Research and Development,28248104,0,,P14416,9606.0,,,,1,0,1,0,0,0
1442586,Literature-derived,"Potency index, ratio of dopamine EC50 to compound EC50 for ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells","Title: Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure._||_Abstract: 1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors. Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties. In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists. Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over -arrestin recruitment at dopamine D2 receptors. The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo. Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.",43,ChEMBL,CHEMBL4010183,20200620,137638973|137640371|137643309|137651936|137659990|137660837,381847923|381849986|381854346|381867052|381884437|381885712,1813,,P14416,Curation Efforts|Research and Development,28248104,0,,P14416,9606.0,,,,1,0,1,0,0,0
1458657,Confirmatory,Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,"Title: Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity._||_Abstract: The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide) exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia.",43,ChEMBL,CHEMBL4041093,20200621,3559|56944860|56944861|56944862|56944863|56944864|56944951|56944952|56944953|56944954|56944955|56944956|56945042|56945043|66800947|66800959|66800965|66801052|66801295|66801344|66801425|66801429|66801430|66801528|66801537|66801561|66801624|66801625|66801701|66801837|66803474|66803497|66803500|66803595|137635884|137651887|137654666,103167216|381837540|381839594|381839834|381840033|381840292|381841008|381843294|381846959|381847671|381849619|381850294|381852011|381852195|381852827|381852996|381854186|381858118|381858193|381861761|381862004|381862654|381863691|381863916|381865143|381865880|381866973|381868510|381870998|381871109|381873017|381878858|381879460|381881107|381882018|381883182|381884162,1813,,P14416,Curation Efforts|Research and Development,28763213,0,,P14416,9606.0,,,,1,0,1,0,1,0
1459199,Confirmatory,Displacement of [3H]N-methylspiperone from recombinant human D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method,"Title: The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over 1-adrenoceptor and D2-like receptor subtypes._||_Abstract: N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine (3) is a potent 5-HT1A receptor and 1d-adrenoceptor (1d-AR) ligand. Analogues 5-10 were rationally designed and prepared to evaluate whether electronic and/or lipophilic properties of substituents in the ortho position of its phenoxy moiety exert any favorable effects on the affinity/activity at 5-HT1A receptor and improve selectivity over 1-ARs. To rationalize the experimental observations and derive information about receptor-ligand interactions of the reported ligands, docking studies, using 5-HT1A and 1d-AR models generated by homology techniques, and a retrospective computational study were performed. The results highlighted that proper substituents in position 2 of the phenoxy moiety of 3 selectively address the ligands toward 5-HT1A receptor with respect to 1-ARs and D2-like receptor subtypes. Methoxymethylenoxy derivative 9 showed the best 5-HT1A selectivity profile and the highest potency at 5-HT1A receptor, behaving as a partial agonist. Finally, 9, tested in light/dark exploration test in mice, significantly reduced anxiety-linked behaviors. Therefore, it may be considered a lead for the design of partial agonists potentially useful in the treatment of disorders in which 5-HT1A receptor is involved.",43,ChEMBL,CHEMBL4041731,20200621,25131876|137639125|137646245,164136250|381848133|381858648,1813,,P14416,Curation Efforts|Research and Development,27662034,0,,P14416,9606.0,45.0,,,1,0,1,0,0,0
1464176,Confirmatory,Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes,"Title: -Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation._||_Abstract: -Arrestin biased G protein-coupled receptor ligands represent important molecular probes and may increase favorable drug action and safety as novel therapeutics. Starting from recently discovered hydroxy-substituted heterocyclic piperazine scaffolds, we have developed a series of dopamine D2 receptor ligands with a pyrazolo[1,5-a]pyridine as secondary pharmacophore that is functionalized in position 3 by a formyl or hydroxyiminomethyl substituent. The ligands, especially the benzoxazinone 9d, were found to stimulate substantial -arrestin-2 recruitment, while being nearly devoid of activity in a GTPS binding assay. Investigating a new series of truncated analogs lacking a secondary pharmacophore, considerable -arrestin-2 recruitment in the absence of G protein activation was found, when a 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one was combined with an N-propyl-substituted 1,4-diazepane (15c). Although 15c displayed reduced potency compared to 9d, the dose-response curves indicate that a hydroxy-substituted heterocyclic primary pharmacophore is sufficient for the functionally selective activation of D2R.",43,ChEMBL,CHEMBL4046973,20200621,60795|137632607|137632761|137634153|137634397|137636298|137637428|137639304|137642033|137643122|137645196|137651322|137653096|137653986|137654511|137655029|137655594|137657322|137657951,103307946|381838339|381838570|381840698|381841034|381843904|381845600|381848381|381852447|381854058|381857111|381866140|381868807|381870089|381870882|381871658|381872516|381879451|381880990,1813,,P14416,Curation Efforts|Research and Development,28870802,0,,P14416,9606.0,,,,1,0,1,0,0,0
1464177,Confirmatory,Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes,"Title: -Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation._||_Abstract: -Arrestin biased G protein-coupled receptor ligands represent important molecular probes and may increase favorable drug action and safety as novel therapeutics. Starting from recently discovered hydroxy-substituted heterocyclic piperazine scaffolds, we have developed a series of dopamine D2 receptor ligands with a pyrazolo[1,5-a]pyridine as secondary pharmacophore that is functionalized in position 3 by a formyl or hydroxyiminomethyl substituent. The ligands, especially the benzoxazinone 9d, were found to stimulate substantial -arrestin-2 recruitment, while being nearly devoid of activity in a GTPS binding assay. Investigating a new series of truncated analogs lacking a secondary pharmacophore, considerable -arrestin-2 recruitment in the absence of G protein activation was found, when a 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one was combined with an N-propyl-substituted 1,4-diazepane (15c). Although 15c displayed reduced potency compared to 9d, the dose-response curves indicate that a hydroxy-substituted heterocyclic primary pharmacophore is sufficient for the functionally selective activation of D2R.",43,ChEMBL,CHEMBL4046974,20200621,60795|137632607|137632761|137634153|137634397|137636298|137637428|137639304|137642033|137643122|137645196|137651322|137653096|137653986|137654511|137655029|137655594|137657322|137657951,103307946|381838339|381838570|381840698|381841034|381843904|381845600|381848381|381852447|381854058|381857111|381866140|381868807|381870089|381870882|381871658|381872516|381879451|381880990,1813,,P14416,Curation Efforts|Research and Development,28870802,0,,P14416,9606.0,,,,1,0,1,0,0,0
1483562,Confirmatory,Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method,"Title: Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor._||_Abstract: Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders. In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions. Here, we report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious. To investigate the structural basis of partial agonism, we performed comparative microsecond-scale molecular dynamics simulations starting from the inactive state of D3R in complex with these enantiomers. Analysis of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations. These receptor models bound with partial agonists may be useful for structure-based design of compounds with tailored efficacy profiles.",43,ChEMBL,CHEMBL4052936,20200622,10456166|42626240|42626318|58358826|122181006|137635743|137639330|137647150|137648255|137653517|137656298|137657276,103402070|124961101|124969027|163334704|318376630|381843105|381848416|381859990|381861617|381869422|381873560|381879252,1813,,P14416,Curation Efforts|Research and Development,27983845,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1543920,Confirmatory,Negative allosteric modulation of recombinant human D2L receptor expressed in Flp-In CHO cells assessed as inhibition of dopamine-induced reduction in forskolin stimulated cAMP accumulation by measuring equilibrium dissociation constant preincubated for 3,"Title: Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D<sub>2</sub> receptor._||_Abstract: We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D<sub>2</sub>R including NAMs with sub-M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).",43,ChEMBL,CHEMBL4341176,20210302,433561|699517|705965|717848|719965|722483|828447|1690520|2100068|2337418|2796104|2808589|4304615|4788910|4795178|4880945|13038297|13038304|46530950|62416153|145712390|155517109|155526849|155533381|155541566|155554026|155554242|155558255|155560792|155563815,134464460|242223422|242413646|318454961|440111267|440112751|440119679|440122670|440127665|440128143|440131345|440134659|440134740|440140919|440144695|440148052|440159564|440160760|440164889|440168474|440170896|440179206|440185483|440190799|440191365|440201392|440207741|440215392|440226489|440229521,1813,,P14416,Curation Efforts|Research and Development,30849613,0,,P14416,9606.0,,,,1,0,1,0,0,0
1543921,Literature-derived,Negative allosteric modulation of recombinant human D2L receptor expressed in Flp-In CHO cells assessed as inhibition of dopamine-induced reduction in forskolin stimulated cAMP accumulation by measuring net cooperativity factor preincubated for 30 mins fo,"Title: Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D<sub>2</sub> receptor._||_Abstract: We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D<sub>2</sub>R including NAMs with sub-M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).",43,ChEMBL,CHEMBL4341177,20210302,717848|719965|722483|828447|1690520|2796104|13038297|13038304|155517109|155558255|155563815,242223422|440119679|440127665|440128143|440131345|440160760|440164889|440179206|440185483|440201392|440215392,1813,,P14416,Curation Efforts|Research and Development,30849613,0,,P14416,9606.0,,,,1,0,1,0,0,0
1543922,Literature-derived,Negative allosteric modulation of recombinant human D2L receptor expressed in Flp-In CHO cells assessed as inhibition of dopamine-induced reduction in forskolin stimulated cAMP accumulation by measuring intrinsic efficacy of the modulator preincubated for,"Title: Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D<sub>2</sub> receptor._||_Abstract: We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D<sub>2</sub>R including NAMs with sub-M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).",43,ChEMBL,CHEMBL4341178,20210302,433561|699517|705965|717848|719965|722483|828447|1690520|2100068|2337418|2796104|2808589|4304615|4788910|4795178|4880945|13038297|13038304|46530950|145712390|155517109|155526849|155533381|155541566|155554026|155554242|155558255|155560792|155563815,134464460|242223422|242413646|318454961|440111267|440112751|440119679|440122670|440127665|440128143|440131345|440134659|440134740|440140919|440144695|440148052|440159564|440160760|440164889|440168474|440179206|440185483|440190799|440191365|440201392|440207741|440215392|440226489|440229521,1813,,P14416,Curation Efforts|Research and Development,30849613,0,,P14416,9606.0,,,,1,0,1,0,0,0
1543923,Literature-derived,Negative allosteric modulation of recombinant human D2L receptor expressed in Flp-In CHO cells assessed as inhibition of dopamine-induced reduction in forskolin stimulated cAMP accumulation by measuring modulation of dopamine efficacy preincubated for 30 ,"Title: Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D<sub>2</sub> receptor._||_Abstract: We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D<sub>2</sub>R including NAMs with sub-M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).",43,ChEMBL,CHEMBL4341179,20210302,433561|699517|705965|717848|719965|722483|828447|1690520|2100068|2337418|2796104|2808589|4304615|4788910|4795178|4880945|13038297|13038304|46530950|62416153|145712390|155517109|155526849|155533381|155541566|155554026|155554242|155558255|155560792|155563815,134464460|242223422|242413646|318454961|440111267|440112751|440119679|440122670|440127665|440128143|440131345|440134659|440134740|440140919|440144695|440148052|440159564|440160760|440164889|440168474|440170896|440179206|440185483|440190799|440191365|440201392|440207741|440215392|440226489|440229521,1813,,P14416,Curation Efforts|Research and Development,30849613,0,,P14416,9606.0,,,,1,0,1,0,0,0
1543924,Literature-derived,Negative allosteric modulation of recombinant human D2L receptor expressed in Flp-In CHO cells assessed as inhibition of dopamine-induced reduction in forskolin stimulated cAMP accumulation by measuring equilibrium dissociation constant up to 100 uM prein,"Title: Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D<sub>2</sub> receptor._||_Abstract: We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D<sub>2</sub>R including NAMs with sub-M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).",43,ChEMBL,CHEMBL4341180,20210302,678806|723144|25020997|155517790|155554237|155558833|155565200|155566589,103765674|440120705|440150282|440191343|440198728|440202873|440218864|440222462,1813,,P14416,Curation Efforts|Research and Development,30849613,0,,P14416,9606.0,,,,1,0,1,0,0,0
1546907,Confirmatory,Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis,"Title: 1-(2'-Bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline and 1,2-Demethyl-nuciferine as Agonists in Human D2 Dopamine Receptors._||_Abstract: Certain D2-like dopamine receptor (DR) agonists are useful therapeutically as antiparkinsonian drugs, whereas D2-like DR antagonists or partial agonists are proven effective as antipsychotics. Two isoquinoline derivatives, 1-(2'-bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline (Br-BTHIQ, 1) and 1,2-demethyl-nuciferine (aporphine, 2), were herein synthesized, and their dopaminergic affinity in cloned human D2R, D3R, and D4R subtypes and their behavior as agonists/antagonists were evaluated. They showed affinity values (Ki) for hD2, hD3, and hD4 DR within the nanomolar range. The trends in affinity were hD4R  hD3R > hD2R for Br-BTHIQ (1) and hD2R > hD4R > hD3R for 1,2-demethyl-nuciferine (2). The functional assays of cyclic adenosine monophosphate signaling at human D2R showed a partial agonist effect for Br-BTHIQ (1) and full agonist behavior for aporphine (2), with half maximal effective concentration values of 2.95 and 10.2 M, respectively. Therefore, both isoquinolines 1 and 2 have emerged as lead molecules for the synthesis of new therapeutic drugs that ultimately may be useful to prevent schizophrenia and Parkinson's disease, respectively.",43,ChEMBL,CHEMBL4344297,20210302,3559|151086|135398737|155568278,103165765|103167216|174513404|440226799,1813,,P14416,Curation Efforts|Research and Development,31933369,0,,P14416,9606.0,198.0,,,1,0,1,0,1,0
1546908,Literature-derived,Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells at 10 uM by radioligand competitive binding analysis relative to control,"Title: 1-(2'-Bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline and 1,2-Demethyl-nuciferine as Agonists in Human D2 Dopamine Receptors._||_Abstract: Certain D2-like dopamine receptor (DR) agonists are useful therapeutically as antiparkinsonian drugs, whereas D2-like DR antagonists or partial agonists are proven effective as antipsychotics. Two isoquinoline derivatives, 1-(2'-bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline (Br-BTHIQ, 1) and 1,2-demethyl-nuciferine (aporphine, 2), were herein synthesized, and their dopaminergic affinity in cloned human D2R, D3R, and D4R subtypes and their behavior as agonists/antagonists were evaluated. They showed affinity values (Ki) for hD2, hD3, and hD4 DR within the nanomolar range. The trends in affinity were hD4R  hD3R > hD2R for Br-BTHIQ (1) and hD2R > hD4R > hD3R for 1,2-demethyl-nuciferine (2). The functional assays of cyclic adenosine monophosphate signaling at human D2R showed a partial agonist effect for Br-BTHIQ (1) and full agonist behavior for aporphine (2), with half maximal effective concentration values of 2.95 and 10.2 M, respectively. Therefore, both isoquinolines 1 and 2 have emerged as lead molecules for the synthesis of new therapeutic drugs that ultimately may be useful to prevent schizophrenia and Parkinson's disease, respectively.",43,ChEMBL,CHEMBL4344298,20210302,3559|151086|135398737|155568278,103165765|103167216|174513404|440226799,1813,,P14416,Curation Efforts|Research and Development,31933369,0,,P14416,9606.0,198.0,,,1,0,1,0,1,0
1593446,Confirmatory,Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method,"Title: Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy._||_Abstract: The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making. Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders. To identify new D4R-selective ligands, and to understand the molecular determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)- N-( m-tolyl)acetamide). Compounds were profiled using radioligand binding displacement assays, -arrestin recruitment assays, cyclic AMP inhibition assays, and molecular dynamics computational modeling. We identified several novel D4R-selective ( Ki  4.3 nM and >100-fold vs other D2-like receptors) compounds with diverse partial agonist and antagonist profiles, falling into three structural groups. These compounds highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.",43,ChEMBL,CHEMBL4392163,20210302,4797946|6466372|10425450|16094666|45361874|109030343|109030515|155511803|155513053|155516494|155522719|155525431|155530763|155536720|155536815|155562395|155563301|155568411|155568867,103503876|103503918|440111698|440113589|440117695|440118212|440118777|440123600|440128439|440130571|440132532|440140737|440149835|440149986|440211928|440214136|440224758|440227125|440228263,1813,,P14416,Curation Efforts|Research and Development,30883109,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1593451,Confirmatory,Displacement of [3H](R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cell membranes measured after 90 mins by scintillation counting method,"Title: Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy._||_Abstract: The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making. Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders. To identify new D4R-selective ligands, and to understand the molecular determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)- N-( m-tolyl)acetamide). Compounds were profiled using radioligand binding displacement assays, -arrestin recruitment assays, cyclic AMP inhibition assays, and molecular dynamics computational modeling. We identified several novel D4R-selective ( Ki  4.3 nM and >100-fold vs other D2-like receptors) compounds with diverse partial agonist and antagonist profiles, falling into three structural groups. These compounds highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.",43,ChEMBL,CHEMBL4392168,20210302,4797946|6466372|10425450|16094666|45361874|109030343|109030515|155530763|155536720|155562395|155563301,103503876|103503918|440117695|440118212|440123600|440130571|440140737|440149835|440211928|440214136|440224758,1813,,P14416,Curation Efforts|Research and Development,30883109,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1616374,Confirmatory,Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method,"Title: Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D<sub>3</sub> Receptor Antagonists and Partial Agonists._||_Abstract: Dopamine D<sub>3</sub> receptors (D<sub>3</sub>R) play a critical role in neuropsychiatric conditions including substance use disorders (SUD). Recently, we reported a series of <i>N</i>-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1<i>H</i>-indole-2-carboxamide analogues as high affinity and selective D<sub>3</sub>R lead molecules for the treatment of opioid use disorders (OUD). Further optimization led to a series of analogues that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP). Among the 3-F-compounds, <b>9b</b> demonstrated the highest D<sub>3</sub>R binding affinity (<i>K</i><sub>i</sub> = 0.756 nM) and was 327-fold selective for D<sub>3</sub>R over D<sub>2</sub>R. In addition, modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examined. Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure <i>R</i>- and <i>S</i>-enantiomers of the four lead compounds. Off-target binding affinities, functional efficacies, and metabolic profiles revealed critical structural components for D<sub>3</sub>R selectivity as well as drug-like features required for development as pharmacotherapeutics.",43,ChEMBL,CHEMBL4415924,20210302,130431288|130431289|130431291|130431294|130431295|130431296|130431306|130431314|130431315|130431316|130431318|130431319|130431328|130431329|146451658|146451661|146451664|146451691,440111877|440122026|440126918|440139378|440141145|440141550|440152147|440154984|440157158|440159640|440160522|440166730|440172590|440189513|440195867|440197499|440212978|440220383,1813,,P14416,Curation Efforts|Research and Development,31526003,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1629095,Confirmatory,Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis,"Title: Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment._||_Abstract: The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention. Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse. Herein, we report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies. Lead compound 19 was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R versus D2R binding selectivity, and its metabolic stability in mouse microsomes. Compound 19 inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization. In addition, pretreatment with 19 also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats. These findings support the D3R as a target for opioid dependence treatment and compound 19 as a new lead molecule for development.",43,ChEMBL,CHEMBL4429153,20210302,130431277|130431279|130431287|130431290|130431303|130431309|130431316|130431317|130431318|130431325|130431334|130431336|130431337|130431340|130431342|130431343|130431351|155514430|155533824|155535272|155552695|155564667,440109820|440111590|440115654|440116525|440126918|440135799|440137411|440145346|440147564|440152147|440152800|440157086|440157122|440158508|440162869|440187374|440188171|440196094|440198160|440205900|440217493|440223950,1813,,P14416,Curation Efforts|Research and Development,27508895,0,,P14416,9606.0,45.0,,,1,0,1,0,1,0
1629121,Confirmatory,Binding affinity to dopamine D2 receptor (unknown origin),"Title: Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment._||_Abstract: The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention. Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse. Herein, we report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies. Lead compound 19 was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R versus D2R binding selectivity, and its metabolic stability in mouse microsomes. Compound 19 inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization. In addition, pretreatment with 19 also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats. These findings support the D3R as a target for opioid dependence treatment and compound 19 as a new lead molecule for development.",43,ChEMBL,CHEMBL4429179,20210302,3033769,103167993,1813,,P14416,Curation Efforts|Research and Development,27508895,0,,P14416,9606.0,,,,1,0,1,0,1,0
